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Raphael Ferreira 
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Abstract  
The advent of genetic engineering tools has initiated an era of manipulating 
microorganisms for the production of valuable compounds for our society. Precise 
engineering of these microbes commonly requires introducing genetic modifications such 
as gene deletion, overexpression, and accurate regulation in order to enhance the production 
of the compound of interest. In this context, the Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/Cas9 technology, adapted from the prokaryotic adaptive 
immune system, has revolutionized our ability to manipulate a broad range of living 
organisms. In contrast to other methods, this technology works like a molecular pair of 
scissors (Cas9) which is guided by a programmable RNA (gRNA) molecule binding at a 
specific location in the DNA. The programmability and time-efficiency offered by this 
technology have in the recent years been successfully exploited in rewiring the metabolic 
network to enhance the production of metabolites used in various areas of industrial 
biotechnology.  
 
In this thesis, I present several studies applying the technological diversity provided by 
CRISPR in the context of building efficient yeast cell factories for the production of 
oleochemicals -sustainable substitutes for plant derived lipids. Since oleochemicals derive 
from lipid products, the main engineering strategies presented essentially focus on fatty 
acid metabolism and its precursors. First, we exploited CRISPR/Cas9 endonuclease 
capacity to extensively remodel yeast lipid metabolism. We showed that the disruption of 
several metabolic fluxes allows to overcome the main limiting steps in fatty acid 
biosynthesis and favors the production of free fatty acids and triacylglycerols, two 
important precursors for the production of oleochemicals. Second, we harnessed the ability 
to precisely regulate genes using the catalytically deactivated form of the Cas9 protein 
(dCas9) coupled to transcription factors for fine-tuning the expression of genes involved in 
lipid biogenesis. Additionally, we proposed a framework for dCas9-based applications 
based on computational techniques for predicting key genes potentially favoring the 
production of yeast endogenous metabolites. Finally, we expanded the CRISPR repertoire 
by building new tools to accelerate yeast cell factory design. We exploited a Type I 
CRISPR-associated endoribonuclease for multiplex genome engineering and 
transcriptional regulation via processing an RNA transcript into multiple gRNAs, and we 
developed a computational tool for designing gRNAs targeting multiple loci at once. In 
summary, the work presented in this thesis provides various ways to efficiently engineer 
yeast metabolism by exploiting the diversity of CRISPR technologies, as well as new tools 
to the community for future engineering strategies.  
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Chapter I: Engineering yeast metabolism 
  
 
 
  
1.1 Prologue 
The concept of microbial biotechnology, when defined as the manipulation of 
microorganisms to convert raw materials into valuable products, can be traced back to the 
early ages of human society (1, 2). Such utilization exclusively relied on basic fermentation 
principles from a narrowed number of organisms, with baker’s yeast figuring prominently 
as a result of its fermentative capability to yield beer, bread, and wine. Arguably, with the 
polyvalence of its fermented products, domestication of baker’s yeast can be praised as one 
of the most critical contributors to the societal growth: with beer and wine as necessary 
means of diplomacy, recreation and socialization, and bread as a universal nutritious food, 
also core to several religious cultures. Though, these processes were uncharacterized until 
the mid-19th century, attributed to the now obsolete theory of spontaneous generation (Fig. 
I-1). Among other seminal works that provided better understanding of the biology behind 
fermentation, Louis Pasteur’s work on deciphering yeast as the catalyst behind the alcoholic 
fermentation has initiated the discipline of microbiology (3). The advent of this discipline 
provided the fundamental characterization of microorganisms on the subject of 
biochemistry, physiology, and cell biology, as well as enhanced the search for new species 
with attracting properties. Consequently, the war economy, and more specifically the 
manufacturing of explosives, greatly benefited from microbial production of acetone and 
glycerol by Clostridium acetobutylicum and Saccharomyces cerevisiae, respectively (4, 5). 
In the medical field, Alexander Fleming’s serendipitous discovery of penicillin, an 
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antibacterial compound secreted by Penicillium chrysogenum, is a landmark in the history 
of treating bacterial diseases (6). While these examples highlight the exploitation of 
intrinsic microbial qualities shaped through evolution to human advantages, these microbes 
naturally only produce a small amount of these compounds. Thus, scientists’ past efforts to 
improve the production have been essentially focused on altering the physiological state of 
these organisms by tweaking their cultivation methods, e.g. addition of sulfite in the media 
to inhibit the conversion of acetaldehyde to ethanol to rewire fluxes towards glycerol (7) 
(Fig. I-1).  
 
 
Figure I-1. Timeline of key event in microbial biotechnology. References: (1, 3, 6, 8–28) 
 
The twentieth century also marks important advances in our fundamental understanding 
of genetics via radiation technologies, e.g. the elucidation of the protein structure (29) 
and the double helix structure of deoxyribonucleic acid (DNA) (8). Additionally, these 
technologies enabled the characterization of a myriad of genetic mapping and 
physiologic characterizations through their mutagenesis properties, e.g. elucidation of 
genes encoding for proteins catalyzing different sugar consuming reactions (30–33) (Fig. 
I-1). Rather than focusing on culture conditions, exposing microorganisms to random 
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mutagenesis allowed targeted selection of strains, with genetic variants leading to desired 
physiological properties.  
 
A major technological revolution occurred in 1973 when Stanley Cohen co-jointly with 
Herbert Boyer developed a technique for merging together strands of DNA and 
artificially introduce them into an organism, coined recombinant DNA technology (9). 
This method allowed for the first time the expression of heterologous genes into a given 
host. Consequently, the first genetic engineering company, Genentech Inc. founded by 
Herbert Boyer and Robert Swanson, famously established the first production of the 
synthetic human protein (somatostatin) in Escherichia coli, with identical properties to 
the naturally occurring one (34). In 1987, Novo produced human insulin in S. cerevisiae 
as a substitute for their insulin obtained from animal origin (35). These engineering 
advances also enabled better control over metabolic pathways in order to enhance the 
production of natural and new compounds. This consequently extended the focus towards 
model organisms such as E. coli and S. cerevisiae, for the production of relevant 
compound rather than natural producers.  
 
Strain optimization using synthetic biology and systems biology 
The advent of genetic engineering tools along with modern information processing 
technologies, have initiated an era of precise control of microbial fermentation for the 
production of diverse compounds. Here, these microbial producers, coined cell factories, 
are not only engineered to express relevant compounds but also extensively characterized 
through incorporated approaches aiming to understand how to further enhance production 
processes. Thus, in the beginning of the 1990s, a discipline studying the directed 
enhancement of metabolic pathways to achieve a specific function, e.g. high production of 
a desired product, was initiated (coined metabolic engineering) (20, 36). Its principles lie 
on the rational application of the knowledge obtained from fundamental biology combined 
with the efficiency of molecular biology tools in cell factory engineering.  
 
Distinctively, sequential and targeted optimization of strain engineering is iteratively 
applied through the so-called Design, Build, Test, and Learn (DBTL) cycle (Figure 1) 
(37). In the design step, the desired target compound defines which chassis to select as well 
as its cellular functions to engineer. For example, based on the complexity of the target 
product, one might start from an organism originally producing the compound or from a 
model organism easier to engineer. The systematic analysis of vast biological datasets can 
enable the prediction of biological entities’ behavior upon metabolic rerouting and majorly 
contributes to the accuracy of strain design. For example, genome‐scale metabolic models 
(GEMs), which are genome‐wide mathematical models, are attractive tools for predicting 
key reactions that potentially favor the production of a metabolite of interest (38–40). 
Furthermore, technological progresses in mapping the various layers of cellular processes 
can also be integrated into strain design, e.g. genomics for genome mapping, 
transcriptomics for RNA mapping, or metabolomics for mapping metabolites etc.  
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Figure I-2. The Design, Build, Test, and Learn (DBTL) cycle for cell factory enhancement.  
 
Based on the design, appropriate biological parts are selected for the building step. For 
example, control over gene expression requires using libraries of promoters or increasing 
the copy of a given gene. This step generally lies on molecular biology approaches to 
assemble multiple DNA fragments together and transform them into the selected host 
organism (41, 42). Additionally, besides rewiring existing (or creating new) pathways 
through these building processes, tools that allow sensitive and rapid screening of candidate 
strains can be also integrated to the design (43, 44). For example, transcription-factor based 
biosensors allow to monitor the intracellular concentration of a specific compound when 
coupled to a fluorescent gene and can ultimately accelerate the throughput of evaluating 
the desired phenotype. An example of utilization of a biosensor will be described in 
Chapter III.  
 
Next, the test phase assesses the performance of the engineered strains for different 
parameters, e.g. measuring the production of the desired product through the determination 
of titer, rate, and yield, using analytic techniques; specific growth behavior and cell 
physiology using bioreactors; or high-throughput screening of strain libraries by tracking 
single cell GFP fluorescence using fluorescence activated cell sorting (FACS). Finally, the 
most optimized strains, i.e. strains giving the best expected output of the study, are analyzed 
to learn which characteristics lie behind these superior performances as well as how to 
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further improve them (Fig. I-2). For example, genome or gene sequencing to identify causal 
mutations in these strains, or, RNA sequencing analysis to identify genes and pathways 
causing physiological changes in these strains (37). 
 
1.2 The last genetic engineering technology 
Metabolic pathway optimization towards a product of interest commonly requires deletions 
of multiple genes, e.g. competitive metabolic pathways, which, in yeast, is traditionally 
performed through iterative cycles of genetic marker integration and removal (45). 
However, these tools are commonly experienced with difficulties in design, synthesis, and 
time-efficiency which altogether prevents fast strain engineering (45).  
 
In the last seven years, one particular technique, named Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR), has been efficiently addressing most of the above-
mentioned challenges in genetic engineering. This technology originates from prokaryotic 
and archaeal immune systems to neutralize phage invasions, and has now been tailored for 
manipulating a broad range of living organisms (24, 46, 47), including cell factories (48).  
 
CRISPR Principles 
First reported in 1987, CRISPR derives from arrays found in the genome of numerous 
bacteria and archaea (49). These arrays are composed of DNA sequences encoding non-
coding CRISPR RNAs (crRNAs), comprised of short direct repeat sequences (DR) 
interspaced with unique ones (spacers), and clustered together with several CRISPR-
associated (cas) genes. These two distinct elements together form the main elements of the 
adaptive immunity against foreign nucleic acid invasion such as phage genomes and 
conjugating plasmids (50, 51). The mediated immunity is divided into two stages: (i) the 
adaptation stage, commonly driven by cas1 and cas2 genes (52), whose function is to 
genomically integrate elements of the phage genome into the beginning of the CRISPR 
loci; and (ii) expression and interference stage, composed of diverse subsystems involved 
in processing of the different spacers and degradation of the invasive viral genome through 
cas nuclease effectors. Interestingly, the constant war against phages has yielded an 
extreme diversification of cas genes and genomic locus architecture and rigorous 
classification of the different CRISPR types and classes remains an ongoing work (53) (54) 
(Box 1).  
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Box 1. Type I, II, and III CRISPR-systems.  
 
Type I systems use Cas6e/Cas6f/Csy4 endoribonucleases (in yellow) to generate CRISPR 
RNAs (crRNAs) by cleaving at the intersection of the hairpin loops in the CRISPR direct repeat. 
The interference stage occurs when the crRNAs bind to its viral complementary strand 
(protospacer), considering the presence of the PAM. Once bound, the multiprotein Cascade 
complex (in grey) recruits Cas3 (in blue) for DNA degradation. 
Type II systems use a trans-activating RNA (tracrRNA) to generate multiple crRNAs. This 
system relies on a single protein, e.g. Cas9, for the interference step.  
Type III systems use Cas6 to produce mature crRNAs. As with type I, type III systems require 
multiple Cas proteins binding to crRNAs, called Csm/Cmr complex. The type III systems can 
either target the viral mRNA or DNA.  
 
Application in genome engineering and gene regulation 
Scientists have since borrowed these different CRISPR-systems to perform complex gene 
editing (48), with the type II system adapted from Streptococcus pyogenes being the most 
widely adopted for genetic engineering and gene regulation (Box 1) (55, 56). This 
technology targets DNA with an endonuclease, CRISPR associated protein 9 (Cas9), which 
is programmed by an RNA, guide-RNA (gRNA). The gRNA is composed of two parts: (i) 
the crRNA, i.e. the transcribed spacer, usually 20 nucleotide long and complement to the 
target DNA (protospacer); and (ii) the tracrRNA, which acts as connecting scaffold with 
Cas9 (24, 57) (Box 1, Fig. I-3). The crystal structure of Cas9 revealed the composition of 
two lobes linked with a bridge helix (BH): the target recognition (REC) whose function is 
involved in binding between the gRNA and the DNA target, and the nuclease lobe (NUC) 
containing the nucleases HNH and RuvC (58) (Fig. I-3). Once the Cas9-gRNA complex is 
bound to the DNA target by base pairing, Cas9 nucleases domains cleave the DNA 
sequence three nucleotides upstream the protospacer adjacent motif (PAM, NGG-3’ for 
Cas9), recognized by the PAM-interacting domain (PI) located in the NUC lobe (58, 59) 
(Fig. I-3). The PAM sequence is juxtaposed to the protospacer region and is required for 
DNA cleavage (Fig. I-3) (60).  
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Figure I-3. The main elements of the CRISPR technology: Cas9 and the gRNA. Cas9 is a 
bilobed multidomain protein composed of the REC lobe whose function assures correct binding 
of the gRNA to the DNA target, and the NUC lobe which contains the two nuclease domains 
(HNH and RuvC) as well as the PAM interacting domain. These two lobes are connected with a 
bridge helix (BH). Cas9 is guided by the gRNA, which is composed of the crRNA, complement 
to the target sequence, and the tracrRNA scaffold connecting with Cas9. Upon recognition of the 
PAM sequence by the formed heteroduplex gRNA:DNA:Cas9, Cas9 nuclease domains ultimately 
cleave the DNA target 3 nt upstream the PAM.  
 
The CRISPR revolution started from a seminal work from Jinek and colleagues showing 
that the crRNA can be programmed to target a specific sequence in vitro, and it can be 
linked with the tracrRNA into a single RNA element (sgRNA, interchangeably used with 
gRNA) (24) (Fig. I-3). Later in January 2013, two independent labs, namely George 
Church’s and Feng Zhang’s labs, showed that these gRNAs could be used for genetic 
engineering human cell lines (47, 61). When targeted to a living organism’s genomic DNA, 
the “blunt” cut initiates the endogenous repair mechanisms, such as HR or non-homologous 
end joining (NHEJ) and thus offers a window to perform genome engineering (Fig. I-4, 
Box 1).  
 
The attractiveness of CRISPR technology also lies in the engineering versatility offered on 
both the nuclease and the guide, as well as its diverse catalogue of cas genes provided by 
the different CRISPR containing living organisms (62). The structural characterization of 
Cas9 has led to the development of mutagenized variants with various catalytic properties, 
e.g. the inactivation of one of the nuclease activity domains (RuvCD10A or HNHH840A, 
Cas9n) to perform a single-strand DNA break (nick); modification of Cas9’s PAM-
interacting domain to increase the recognition range PAM sequences, e.g. Hu and 
colleagues evolved Cas9 to recognize NG, GAA and GAT as PAM sequences (63); or 
modifications reducing the likelihood of interaction between the gRNA and an off-target 
genomic sites (64, 65). Complete disruption of the two nuclease activities (RuvCD10A and 
HNHH840A) results in a catalytically inactive Cas9 or dead-Cas9 (dCas9) which has been 
exploited as a mean of interfering with transcriptional regulation by sterically hindering the 
transcriptional activity of the RNA polymerase (66, 67). Additionally, dCas9 can be fused 
to transcription factors such as the mammalian transcriptional repressor domain Mxi1 to 
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further improve the efficiency of repression, or with the tripartite VP64-p65-Rta (VPR), 
composed of three different transcription activators, for gene activation (Figure I-5) (68–
72). Finally, other kind of CRISPR nucleases such as Cas12a (also known as Cpf1) from 
Franciscella novocida, and the recently identified CasX (also known as Cas12e) from 
Deltaproteobacteria bacterium, whose small size and different PAM recognition 
specificities ultimately make them established alternatives to Cas9 (73–75). 
 
 
 
 
Figure I-4. CRISPR/Cas9 genome editing and gene regulation. a. Genome editing using 
CRISPR/Cas9 technology. b. Gene regulation using dCas9-based technologies.  
 
 
 
Thus, the programmability of the gRNA allows the user to target virtually any position in 
the genome of interest, considering the presence of a PAM sequence. However, correct 
functionality of the gRNA is also subject to several parameters depending on the desired 
engineering approach, e.g. improper GC content can affect the stability of the RNA 
secondary structure (76), or targeting a non-unique region might create unintended binding 
elsewhere in the genome, called off-targets (77). For most of CRISPR/dCas9-based 
applications, the distance to the TSS affect has been characterized as an important factor 
for proper regulation, e.g. -100 to 0bp for downregulation. Nucleosomes, the main 
component of the chromatin structure, as well as transcription factors can also sterically 
hinder proper binding of the gRNA (78). Further modifications on the gRNA are usually 
introduced in the spacer, e.g. to improve on-target specificity, or in the scaffold by adding 
extra RNA stem-loops, e.g. self-processing elements to prevent degradation. Additionally, 
processing elements are also exploited for multiplexing by collocating these cleavable 
elements between each gRNA sequence, which I will further detail in Chapter IV.  
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Figure I-5. Key features considered for gRNA design. GC content affects RNA secondary 
structure which can impede proper binding to the DNA target or to Cas9. Depending on the 
nuclease employed, the presence of a PAM in the target is critical for genome editing to occur. 
Off-target analysis which is routinely performed to prevent unwanted binding in the genome. For 
most of CRISPR/dCas9-based applications, the distance to the TSS affect has been 
characterized as an important factor for proper regulation, e.g. -100 to 0bp for downregulation. 
Nucleosome occupancy as well as transcription factors can influence proper binding of the gRNA.  
 
1.3 Engineering S. cerevisiae for the production of oleochemicals 
Quintessential cell factory 
Throughout its extensive utilization, S. cerevisiae’s metabolism has been significantly 
characterized, and it is, consequently, one of the favored microbes for the production of 
many valuable compounds (79–81). It was the first eukaryotic organism to be sequenced 
and extensive knowledge regarding its metabolism and physiology is available into several 
databases (21). Based on this knowledge, the reconstruction of its cellular metabolism has 
been achieved on the genome scale, generating so-called GEMs, which ultimately allows 
quantitative predictions of metabolism, e.g. estimating the growth rate under certain culture 
conditions or simulating gene deletions (39, 80). Additionally, numerous pathways also 
occurring in higher eukaryotes such human and plant are highly conserved in yeast, which 
not only has allowed to elucidate the molecular mechanisms of these pathways, e.g. the 
discovery of autophagy in S. cerevisiae, but also facilitated the expression of heterologous 
genes from these organisms (82, 83). It has a strong track-record for large-scale industrial 
cultivation, due to its short generation time (doubling time of approximately 2 h at 30°C), 
and robustness to harsh environments such as low pH and resistance to phages, known to 
frequently fault bacteria-based cultivations. It naturally possesses an extremely efficient 
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homologous recombination system (HR) which greatly facilitates genome engineering such 
as the insertion of multiple genetic elements. Significant scientific contributions also arose 
from the use of the yeast collections, e.g. a yeast library carrying each individual gene 
knockout, particularly in screens for synthetic lethality and investigating novel drug targets 
(84–86).  
Anthropocene era – the undesired exponential 
My graduate studies have sorrowfully coincided with records of heatwaves that stormed 
Europe, with France hitting its all-time temperature record in June 2019 with 46°C in the 
southern village of Gallargues-le-Montueux (87). Concentrations of greenhouse gases 
(GHGs) — including CO2, N2O, and CH4 — in the atmosphere have drastically increased 
since the beginning of the industrialization of our society, primarily coming from our 
dependence on fossil sources (88). Experts’ reports regarding the forecast on the climate 
are unequivocal: inaction on the rising global GHG emissions will be ineluctably followed 
by increased temperature at higher frequency (89). The global increase of temperature is 
currently devastating several ecosystems, and recent predictions have placed 1.000.000 
species threatened with extinction, with Bramble Cay melomys (Melomys rubicola) being 
the first mammal recognized as extinct due to climate change (90–92). Additionally, the 
permafrost region which holds twice more carbon than the atmosphere could not only 
collapse as the temperature rises, but would also transition from a white reflecting surface 
region to a dark absorbing one, ultimately creating a snowball effect (93, 94). Thus, 
substantial efforts are needed to prevent reaching the “2°C above pre-industrial era” 
threshold established at the Conference of the Parties to the United Nations Framework 
Convention on Climate Change (COP21) in 2015.  
 
Production of oleochemicals in S. cerevisiae 
In order to palliate the harmful effect of climate change, there has been an increasing 
interest in exploiting renewable resources for the synthesis of oleochemicals (95) (Fig. I-
4). Oleochemicals are described as a class of hydrocarbon compounds, i.e. composed of 
carbon and hydrogen, generally extracted from vegetable lipids (96). These lipids are 
constituted of fatty acids (FAs) esterified with different backbones, with triacylglycerols 
(TAGs) - three FA units esterified to a glycerol backbone - as the main component (97). 
Depending on the origin, chemical processing of these lipids into basic oleochemicals can 
yield different products such as free fatty acids (FFAs), fatty alcohols, alkenes, or alkenes, 
whose value depends on their acyl chain length, saturation level, terminal groups, and 
applications (98).  
 
While oleochemicals offer a cost-effective substitute for petrochemicals and fuels, 
important sustainability and technical challenges from their utilization remain to be 
addressed. First, many of these oleochemicals derive from the extraction of lipids from 
exotic plant species that only grow in specific regions on Earth, which ultimately creates 
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economic instabilities as supply chains are controlled by few suppliers; e.g. 85% of the 
world palm oil comes from the Malay Archipelago (99). Also, driven by the increasing 
demand for palm oil, large expansion of the land used to produce it has led to significant 
deforestation and biodiversity loss, e.g. annual conversion of 270,000 ha of tropical forest 
conversion to palm trees from 2000–2011 in the main exporting countries (100). Finally, 
engineering these plants remains extremely challenging due to their slow growth and the 
lack of efficient tools. Altogether, efforts to alternatively produce oleochemicals by yeast 
and other microbes through metabolic engineering have increasingly been investigated in 
the recent years (98, 101, 102) (Fig. I-6).  
 
 
 
 
Figure I-6. Biorefinery for the production of oleochemicals. Pre-treatment and hydrolysis of 
biomass resources such as corn, grass or wood, yield sugars that can be fermented by microbial 
cell factories for generating high-value oleochemicals. Applications of oleochemicals range 
transportation fuels, cosmetics, to lubricants and bioplastics.  
 
 
Since oleochemicals are lipid-derived products, common metabolic engineering strategies 
applied for microbial cell factories often focus on redirecting carbon flux from sugar to the 
fatty acid metabolism (Fig. I-7). In S. cerevisiae, the synthesis of FAs is catalyzed by the 
fatty acid synthase (FAS) complex, encoded by the FAS1 and FAS2 genes, where malonyl-
CoA and acetyl-CoA are used as building blocks to form acyl-CoAs (103). Malonyl-CoA 
is synthesized from acetyl-CoA by acetyl-CoA carboxylase (Acc1), an enzyme tightly 
regulated at the transcriptional level by Ino2/4 and Opi1, as well as at the post-
transcriptional level by Snf1, which altogether makes this reaction the rate limiting step of 
the FA biosynthesis (104–106). Malonyl-CoA is iteratively utilized by the FAS complex 
as an elongation block to extend the size of the acyl-chain. In S. cerevisiae, most of the 
acyl-CoA generated by the FAS complex is naturally composed of long chain fatty acids 
(LCFAs; C16 and C18), complemented by a small fraction composed of C12 and C14. 
These FAs can be further elongated to very long chain fatty acids (VLCFAs; C20 up to 
C26), carried out by elongases (Elo1, Elo2, and Elo3), located at the endoplasmic reticulum  
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Figure I-7. Fatty acid biogenesis and lipid metabolism in S. cerevisiae. Metabolites. Gro3P: 
glycerol-3-phosphate; PA, phosphatidic acid; CDP-DAG: cytidine diphosphate diacylglycerol; 
PC: phosphatidylcholine; PE: phosphatidylethanolamine; PI: phosphatidylinositol; PS: 
phosphatidylserine; ES: ergosterol; SE: sterol esters; DAG: diacylglycerol; TAG: triacylglycerol; 
β: β-oxidation. Gene names. ACC1: acetyl-CoA carboxylase; FAS1/2: fatty acid synthase; 
FAA1/4: fatty acyl-CoA synthetases, SCT1 and GPT2: glycerol-3-phosphate O-acyltransferase; 
GUT2: glycerol-3-phosphate dehydrogenase; ALE1: lysophospholipid acyltransferase; SLC1: 1-
acyl-sn-glycerol-3-phosphate acyltransferase; POX1: fatty acyl-CoA oxidase, DGA1: 
diacylglycerol acyltransferase, LRO1: phospholipid:diacylglycerol acyltransferase, ARE1 and 
ARE2: acyl-CoA:sterol acyltransferases; PXA1/2: subunit of peroxisomal ABC-transporter; 
ELO1/2/3: fatty-acid elongases; TGL3/4/5: TAG lipases; TGL1: sterol esterase; PLB1/2/3: 
phospholipases B; NTE1: serine esterase; PAH1: phosphatidic acid phosphohydrolase; CDS1: 
phosphatidate cytidylyltransferase; DPP1: diacylglycerol pyrophosphate phosphatase; LPP1: 
lipid phosphate phosphatase; PIS1: CDP-diacylglycerol-inositol 3-phosphatidyltransferase; 
CHO1: phosphatidylserine decarboxylase proenzyme; CHO2: phosphatidylethanolamine N-
methyltransferase; OPI3: phosphatidyl-N-methylethanolamine N-methyltransferase 
 
 
(ER), as well as desaturated at the Δ9 position by the only fatty acid desaturase Ole1 (Fig. 
I-7) (107–110). Since the acyl chain length and saturation level of oleochemicals determine 
their value and application, several strategies to tweak the abundance of the different FAs 
have been relying on fine-tuning these genes, e.g. overexpression of ELO2 to accumulate 
C22 FAs (111), engineering the endogenous FAS genes to indrocuce heterologous parts 
which ultimately favored the generation of short-chain FAs (SCFAs) (112), or increasing 
the rate of C18:1 by replacing OLE1 by the Δ9 desaturase gene, ChDes9‐2, from Calanus 
hyperboreus with higher substrate specificity for C18:0 (113).  
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Intracellular pools of acyl-CoAs are then either used as substrates for generating major lipid 
classes in the cell, namely phospholipids (PLs), TAGs, sterol esters (SEs), and 
sphingolipids, or, imported to peroxisomes for degradation to acetyl-CoA through the β-
oxidation pathway (Fig. I-7) (114). For PLs and TAGs, acyl-CoAs are sequentially 
esterified into a glycerol backbone via different acyl transferases, producing phosphatidic 
acid (PA) (Fig. I-7) (115). PA is a key intermediate of yeast glycerophospholipid 
biosynthesis as it can either be metabolically converted to diacylglycerol (DAG) for the 
biogenesis of TAGs, or to cytidine diphosphate diacylglycerol (CPD-DAG), precursor of 
the different PL classes. SEs synthesis is catalyzed by the acyl-CoA:sterol acyltransferases, 
encoded by ARE1 and ARE2 (116). The hydrolysis of the major lipid classes involves 
lipases and esterases, and results in a cleavage of the esterified fatty acyl-chain into FFAs 
(115, 117). These FFAs are directly converted to acyl-CoA by one of the fatty acyl-CoA 
synthetases, mainly Faa1 and Faa4 in the cytosol, and Faa2 for degradation through β-
oxidation in the peroxisome (Fig. I-7).  
 
Besides FFAs and TAGs, synthesis of oleochemicals is not feasible endogenously in S. 
cerevisiae. Thus, efforts have been made, these recent years, towards identifying critical 
heterologous enzymes catalyzing reactions producing these downstream products (98, 
102). Fatty alcohols are used in numerous industrial applications, e.g. surfactants, 
detergents, and cosmetics (Fig. I-6). Production of fatty alcohols in S. cerevisiae can 
efficiently be achieved from FFAs in a two-step reaction, a carboxylic acid reductase, e.g. 
from Mycobacterium marinum, converts FFAs to fatty aldehydes which can be then 
converted to fatty alcohols using the endogenous alcohol dehydrogenase (e.g. Adh5) (Fig. 
I-8). This strategy is usually coupled to removing genes responsible for the degradation of 
the intermediate metabolites, i.e. the main acyl-CoA activating genes (FAA1 and FAA4) as 
well the first step of the beta-oxidation (POX1) for FFA degradation, and the fatty aldehyde 
dehydrogenase which converts fatty aldehydes back to FFAs (HFD1) (Fig. I-8) (118–120). 
Another route can be achieved using acyl-CoAs as main substrate through fatty acyl-CoA 
reductases (FAR) enzymes (121). As mentioned above, fatty acid metabolism is tightly 
regulated, which ultimately limits metabolic engineering strategies focusing on improving 
acyl-CoA pools, in comparison with FFAs which can accumulate to high levels (200 fold 
higher than fatty acyl-CoA) by the removal of FAA1 and FAA4 (119).  
 
Fatty alcohols can be esterified with acyl-CoAs by wax ester synthases to produce wax 
esters (WEs) (Fig. I-8) (121–123). WEs are traditionally extracted from the seed oil of 
Simmondsia chinensis (jojoba) and are applied in a broad range of industrial applications, 
e.g. cosmetic, anti-inflammatory ointment, and candles (124). For the production of WEs 
in S. cerevisiae, since fatty acids present in the jojoba oil are mostly composed of C20:1 
and C22:1, recent studies have extensively focused on obtaining the required acyl chain 
length by overexpressing ELO2, to push from C16/18 to C20/22, and removing ELO3, to 
prevent elongation to C24/26, together with expressing heterologous FAR with higher 
substrate affinity towards these long chain fatty acids (111, 125, 126). As with fatty 
alcohols, alkene and alkanes can be derived from fatty aldehydes through fatty aldehyde 
deformylating oxygenases, or from acyl-CoAs using decarboxylases (127, 128). In contrast 
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to WEs, alkanes and alkenes usually require shorter acyl chain (C7 to C13) for industrial 
application, which is challenging to accumulate in S. cerevisiae due to the fatty acid 
machinery predominantly generating C16 and C18 fatty acid precursors (129). Recent 
studies have enabled the synthesis of medium chain alkanes and alkenes in S. cerevisiae by 
primarily engineering endogenous FAS genes into a single enzyme with domains borrowed 
from other fungal species, yielding a FAS complex generating short and medium chain 
fatty acids (112, 130).  
 
 
 
Figure I-8. Strategies for the production of oleochemicals in S. cerevisiae. Acc1: acetyl-
CoA carboxylase 1; Fas1/2 : fatty acid synthase 1 and 2; Pox1: fatty-acyl coenzyme A oxidase; 
Mcr: malonyl-CoA reductase; PhlD: type III polyketide synthase; Ole1: fatty acid 
monodesaturase; TesA: acyl-CoA thioesterase I; Faa1/4: fatty-acid activation 1 and 4; Pah1: 
phosphatidic acid phosphohydrolase 1; Dga1: diacylglycerol acyltransferase 1; Tgl3: 
triacylglycerol lipase 3; Ws: wax ester synthase; Far: fatty acyl-CoA reductase; Aar: acyl-ACP 
reductase; Hfd1: Fatty aldehyde dehydrogenase; Ado: aldehyde-deformylating oxygenase; 
Adh5: alcohol dehydrogenase 5. Blue arrows: endogenous enzymes from S. cerevisiae, in 
purple: heterologous enzymes.  
 
Other engineering strategies include the engineering of permeases to secrete toxic 
oleochemicals, e.g. fatty alcohols (131–135). Also, since S. cerevisiae is an eukaryote, 
subcellular compartmentalization of complete metabolic pathways can be achieved in 
different organelles such as the mitochondria, ER, and peroxisomes, with increased 
efficiency due to the availability of certain metabolites, e.g. unique presence of heme in the 
mitochondria (136). Besides acetyl-CoA and malonyl-CoA, FA synthesis consumes large 
amounts of NADPH, whose main cellular formation takes place in the oxidative pentose 
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phosphate pathway (PPP) (107). Thus, examples of recent strategies have rewired fluxes 
from glycolysis through the PPP to generate more NADPH, as well as expressing enzymes 
regenerating NADPH, e.g. NADP+-dependent glyceraldehyde-3-phosphate dehydrogenase 
(GAPN) from Bacillus cereus which converts 3-P-glyceraldehyde to 3-P glycerate in a 
single reaction using NADP+ as co-factor (137, 138).  
1.4 Scope of the thesis 
In Chapter I, I have introduced the concept of metabolic engineering metabolism and how 
it can be purposely modified to enhance the production of metabolites of interest. The 
DBTL cycle which leverages tools from systems biology and synthetic biology, is 
commonly implemented to develop efficient cell factories. Building a strain includes 
introducing genetic modifications such as gene deletion, overexpression, and exact 
regulation to improve pathway efficiency and product yield. In this context, CRISPR has 
in the recent years been adapted for manipulating a broad range of living organisms, 
including their metabolism. This chapter has also been focusing on giving an overview of 
CRISPR technology from its discovery to its application in living organisms (Paper I). 
This thesis will explore how CRISPR technologies can be applied in the context of building 
efficient yeast cell factories for the production of oleochemicals. 
 
In Chapter II, I will present two studies underlining the time-efficiency of CRISPR 
technology for remodeling S. cerevisiae’s lipid metabolism for increasing the production 
of free fatty acids and triacylglycerols, respectively. I will present results from Paper II, in 
which we generated a free fatty acid production strain by minimizing the lipid metabolism 
network and deregulating different feedback loops. Then results from Paper III will be 
presented, where several metabolic fluxes were engineered to overcome the main limiting 
steps in fatty acid biosynthesis, ultimately generating a strain accumulating the highest 
levels of triacylglycerols reported in S. cerevisiae so far.  
 
After focusing on genome remodeling by principally removing multiple genes involved in 
a particular pathway, Chapter III will explore dCas9-based technologies for fine-tuning 
of biosynthetic pathways, i.e. precise control over gene expression. This is often a key step 
for the efficient synthesis of a particular target compound but is relatively challenging to 
achieve through traditional engineering strategies. The CRISPR system, besides its 
efficient endonuclease activity, can enable transcriptional regulation via the catalytically 
deactivated form of the Cas9 protein coupled to transcription factors. This chapter will be 
supported by two studies: In Paper IV, we benchmarked two dCas9-mediated systems for 
controlling the expression of 14 genes targeted by a total of 101 gRNAs. We also 
demonstrated the impact of single and multiplex gRNA strategies for reprogramming 
expression of multiple genes in the isoprenoid and TAG biosynthetic pathways. In Paper 
V, we proposed a framework based on computational techniques for predicting key genes 
that potentially favor the production of the endogenous metabolites, and on the versatility 
of CRISPR technology for fine-tuning gene expression coupled with an intracellular 
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biosensor for selecting high-producing cells. This was carried out by designing targeted 
gRNA libraries to explore multiple metabolic pathways. 
 
In Chapter IV, we seek to expand the CRISPR repertoire by building new tools to 
accelerate microbial cell factory design. This chapter is supported by several studies: (i) 
exploiting CRISPR-associated endoribonuclease Csy4 for multiplex genome engineering 
and transcriptional regulation via processing an RNA transcript into multiple gRNAs 
(Paper VI), (ii) using promiscuous on-target score of a given gRNA which ultimately 
allows to target multiple loci at once (Paper VII), and (iii) characterization of other 
CRISPR nucleases.  
 
Finally, Chapter V will be the concluding chapter of the thesis focusing on the future 
perspectives of CRISPR technology in engineering metabolism and its applications in 
yeast. This section will emphasize the recent technologies that have been developed and 
are yet to be applied to yeast metabolism. Additionally, comments will be made regarding 
the future utilization of S. cerevisiae as chassis for metabolic engineering and advancing 
CRISPR technologies.  
 
 
 
 
 
Graphical abstract of the thesis. 
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Chapter II: Remodeling specific metabolic pathways 
 
 
 
2.1 Towards a minimal lipid metabolism (Paper II) 
As previously mentioned, FFAs are attractive endogenous chemicals that can readily be 
converted into a broad range of industrial compounds (Fig. I-5). These metabolites are 
mostly extracted from plant oils after hydrolysis of TAGs, and engineering efforts towards 
a more sustainable process through the development of microbial cells capable of 
efficiently converting sugars into FFAs are actively being sought. Fatty acid synthesis is 
strongly regulated by feedback mechanisms and FFAs are found natively only in low levels 
(less than 0.1% of dry cell weight) (114). These challenges make, theoretically, S. 
cerevisiae an unfavored chassis for the production of these compounds. In Paper II, 
harnessing CRISPR efficiency, we sought to investigate the dynamics of lipid metabolism 
surrounding FFA biosynthesis by minimizing S. cerevisiae’s lipid metabolic network 
towards its essential components, i.e. fatty acid and membrane lipid biosynthesis.  
 
In S. cerevisiae, the main routes to generate FFAs come from hydrolysis of the main lipid 
classes, i.e. TAG lipases, e.g. TGL3, TGL4, and TGL5, degrading TAGs into DAGs and 
FFAs; sterol esterase, e.g. TGL1 and YEH1, degrading SEs into sterols and FFAs; and 
phospholipases, e.g. PLB1, PLB2, and PLB3, which cleave the acyl-chain from 
phospholipids (139–143). As mentioned above, FFAs derived from hydrolysis of the main 
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lipid classes, are directly converted to acyl-CoA by fatty acyl-CoA synthetases which keeps 
FFA levels in the cytoplasm low. Previous engineering strategies have shown that deletion 
of the two main acyl-CoA synthetase genes FAA1 and FAA4 results in de-regulation of 
fatty acid biosynthesis and over-accumulation of FFAs orders of magnitude above a wild-
type strain. This double deletion is usually the starting platform strain for metabolic 
engineering of S. cerevisiae for the production of FFAs. To further prevent FFA and acyl-
CoA degradation and provide a more constrained lipid metabolism network, deletion the 
fatty acyl-CoA oxidase encoded by POX1, which catalyzes the first step of the β-oxidation 
pathway located in the peroxisomes results in a strain (RP02) accumulating to 53 
mg∙gDCW-1 of FFAs, significantly higher than wild-type levels.  
 
 
 
Figure II-1. Simplified lipid metabolism fluxes and genes in S. cerevisiae and the effect of 
disrupting lipid droplet formation on FFA biogenesis. a. The lipid species experimentally 
quantified in blue: PA, phosphatidic acid; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; SE, sterol esters; 
TAG, triacylglycerols; with Free Fatty Acids in red as it is the main metabolite studied. Genes 
highlighted in red are targeted for deletion in the RP09 strain: fatty acyl-CoA synthetases FAA1 
and FAA4, fatty acyl-CoA oxidase POX1, diacylglycerol acyltransferase DGA1, 
phospholipid:diacylglycerol acyltransferase LRO1, and acyl-CoA:sterol acyltransferases ARE1 
and ARE2. b. Total FFAs were quantified for the wild-type wt, RP02 strain lacking fatty acid 
reactivation (FAA1 and FAA4 deletions), β-oxidation (POX1 deletion), and RP09 with additionally 
deleted storage lipid formation (DGA1, LRO1, ARE1, and ARE2 deletion).  
 
Next, we investigated the role of the storage-lipid formation pathways in FFA biogenesis. 
Thus, we deleted the main storage lipid biogenesis genes, DGA1 encoding diacylglycerol 
acyltransferase, LRO1 encoding phospholipid:diacylglycerol acyltransferase, and ARE1 
and ARE2 encoding acyl-CoA:sterol acyltransferases (Fig. II-1). The resulting strain 
(RP09: Δfaa1 Δfaa4 Δpox1 Δdga1 Δlro1 Δare1 Δare2), did not significantly accumulate 
more FFAs compared to RP02 (53 mg∙gDCW-1 and 57 mg∙gDCW-1 respectively, Student’s 
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t-test p-value > 0.05). Thus, the combinatorial deletion of the storage-lipid formation genes 
shows that FFAs biogenesis is independent of the lipid storage pathway. 
 
The strain RP09 allowed for further study of the fatty acid dynamics and pathways involved 
in FFA formation, since it was devoid of neutral lipids and therefore these could be 
excluded from the fatty acid pools existent in the cell. Here, we hypothesized that removal 
of storage lipid formation could have led to an accumulation of intermediates such as 
diacylglycerols (DAGs), which are formed by dephosphorylation of PA. Notably, previous 
reports have demonstrated that high-levels of PA reduce translocation of the transcriptional 
regulator Opi1 to the nucleus, which ultimately prevent its binding to Ino2. Since Ino2 is a 
transcription factor activating several lipid biosynthesis genes, we sought to increase PA 
levels by removing the dephosphorylation step from PA to DAG. Deletion of the main 
phosphatidate phosphatases encoded by PAH1, LPP1 and DPP1, from RP09 resulting in 
the strain MLM1.0 (MLM1.0: Δfaa1 Δfaa4 Δpox1 Δdga1 Δlro1 Δare1 Δpah1 Δlpp1 
Δdpp1), accumulated a total of 102 mg∙gDCW-1 FFAs, a 98% increase from RP09. 
Removal of the phosphatidate phosphatases resulted in exclusive use of PA for 
phospholipid biosynthesis, combined with the deregulation through PA signaling, 
phospholipid levels were subsequently increased by 8-fold compared to RP09, reaching 30 
mg·gDCW−1 (Fig 3c).  
 
 
 
Figure II-2. Effect of deleting the main phosphatidate phosphatases on the FFA levels. a. 
Deletion of the main phosphatidate phosphatases activates the signaling mechanism linking PA 
accumulation and the up-regulation of fatty acid biosynthesis through Opi1. PA binds to Opi1, 
which indirectly causes an up-regulation of ACC1, FAS1, and FAS2 genes. b. Total FFA 
quantification of MLM1.0 compared with strains RP09, RP02, and the control strain (wt).  
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While phosphatidylserine (PS) and cardiolipin (CL) remained unchanged and present in 
low percentages compared to RP09, a significant accumulation of phosphatidylcholine 
(PC), phosphatidylethanolamine (PE) and phosphatidylinositol (PI) was observed in 
MLM1.0 (Figure 3). Notably, we observed that the accumulation of phospholipid was 
associated with a formation of large membrane structures in MLM1.0 compared to WT, 
RP02, and RP09 (Fig. II-3), in accordance with previous reports which characterized the 
expansion of internal ER and nuclear membrane structures upon Opi1 deregulation.  
 
 
 
 
 
 
Figure II-3. Phospholipid levels in strains RP09, MLM1.0 and the resulting effect on ER 
membrane. a. PI, phosphatidylinositol; PS, phosphatidylserine; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; CL, cardiolipin. b. Transmission electron microscopy of strains 
generated in this study Observed stacked membrane structures in strain MLM1.0 marked with a 
red arrow.  
 
 
 
Since we observed a combined increase of both FFAs and phospholipids in MLM1.0, we 
sought to investigate the link between these two lipid classes by targeting the main 
phospholipase B genes, namely PLB1 and PLB2. These genes encode for enzymes 
catalyzing the hydrolysis of acyl chains from phospholipids at positions sn-1 and sn-2. 
Here, deletion of PLB1 and PLB2 (MLM1.0 + Δplb1 + Δplb2: Δfaa1 Δfaa4 Δpox1 Δdga1 
Δlro1 Δare1 Δpah1 Δlpp1 Δdpp1 Δplb1 Δplb2) led to significant decrease of FFAs and an 
increase of phospholipids by 46% and 105% respectively (p value < 0.05; Student’s t-test: 
one-tailed, two-sample equal variance) (Fig. II-4). This result indicates that phospholipases 
play an important role in cytosolic and extracellular FFA biogenesis, particularly when the 
acyl-CoA flux is redirected towards phospholipids. 
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Figure II-4. Effect of deletion of the main phospholipase genes PLB1 and PLB2 on FFA 
and phospholipid levels. a. Simplified overview of phospholipid synthesis and degradation 
pathway. b. FFA quantification c. Phospholipid quantification. d. Distribution of FFA acyl classes 
distribution.  
 
This hypothesis is reinforced by the acyl-chain class distribution composing of the secreted 
FFAs which showed a decrease of unsaturated FAs (C16:1 and C18:1) from 62% in RP09 
to 56% in MLM1.0, as PLs are mostly composed of unsaturated FAs (129). 
 
2.2 “Maximizing” lipid metabolism (Paper III) 
As mentioned in Chapter I, TAGs are valuable versatile compounds that can be harnessed 
for biofuel production as well as for nutrition and health (144). TAGs are comprised of 
three fatty acids esterified with a glycerol backbone, and are stored, together with SEs, in 
lipid bodies (also referred as lipid droplets (LD)) (115, 117). LDs are composed of a 
monolayer of phospholipids loaded by several proteins whose roles impact LD biogenesis, 
cellular distribution, and degradation (145). TAGs serve as an important storage form of 
energy which, upon requirement, are hydrolyzed by lipases to release DAGs and fatty acids 
required for membrane synthesis (146). In laboratory condition, S. cerevisiae does not 
naturally accumulate high amounts of TAGs, with levels reaching ~1% of its cell dry 
weight (145). This is significantly lower than oleaginous species such as Yarrowia 
lypolitica that can accumulate TAGs up to >70% of their dry weight (147, 148).  
 
In this study, in order to increase levels of TAGs we sought to perform three distinct 
engineering strategies: (i) increase fatty acid biosynthesis, (ii) push fluxes from PA to 
TAGs instead of phospholipids, and (iii) prevent any degradation of our desired product. 
For the first two steps, we co-overexpressed genes encoding enzymes catalyzing the first 
and last steps of TAG biogenesis, namely the conversion of acetyl-CoA to malonyl-CoA 
by ACC1 and the conversion of PA to DAG (PAH1) and DAG to TAGs (DGA1). In that 
regard, we used a deregulated mutant version of ACC1, ACC1S659A/S1157A (ACC1**), 
expressed under control of the promoter HXT7p that leads to high levels of expression 
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under low glucose concentrations. We genomically integrated one additional copy of PAH1 
and DGA1 each, expressed under control of strong constitutive promoters. The resulting 
strain, ADP (ADP: HXT7p-ACC1** + PGK1p-PAH1 + TEF1p-DGA1) accumulated 129 
mg∙gCDW-1 of TAGs, i.e. a 10-fold increase in comparison to the reference strain (Fig. II-
2). Expectedly, the accumulation of TAGs also led to an increased number of LDs, as their 
formation is driven by the synthesis of TAG and SE (Fig. II-6) (117). 
 
 
 
Figure II-5. Metabolic engineering strategy for overproducing TAGs. a. Engineering strategy 
used for increasing TAG levels. Highlighted in green are genes overexpressed, ACC1** (acetyl-
CoA carboxylase), DGA1 (diacylglycerol acyltransferase) and PAH1 (phosphatidic acid 
phosphohydrolase). Highlighted in red are deleted genes, GUT2 (glycerol-3-phosphate 
dehydrogenase), ARE1 (acyl-CoA:sterol acyltransferase), TGL3/4/5 (triacylglycerol lipases), 
PXA1 (subunit of peroxisomal ABC-transporter), POX1 (fatty acyl-CoA oxidase), and FAA2 (fatty 
acyl-CoA synthetase). PLs: phospholipids b. TAG levels of the engineered strains.  
 
Next, we sought to prevent TAGs from degradation by removing the three main TAG 
lipases, namely Tgl3, Tgl4, and Tgl5, which has been reported to increase TAG levels 
(139). Additionally, as neutral lipids stored in LDs are normally composed of 50% TAGs 
and 50% SEs, we removed sterol ester formation through deletion of ARE1 in order to 
obtain a larger fraction of the neutral lipids in form of triacylglycerols. The resulting strain, 
RF08 (RF08: HXT7p-ACC1** + PGK1p-PAH1 + TEF1p-DGA1 Δtgl3 Δtgl4 Δtgl5 Δare1), 
accumulated 218 mg∙gCDW-1 TAGs, a 68% increase in TAGs levels compared to the 
previous strain, ADP (p value < 0.05; Student’s t-test: one-tailed, two-sample equal 
variance) (Fig. II-5). These results indicate a potential direct turnover of TAGs triggered 
upon their accumulation, in agreement with previous report showing that lipase activity is 
affected by neutral lipid levels (140).  
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Figure II-6. Lipid droplet staining of strains IMX581 and ADP. Lipid droplets were stained with 
BODIPY and analyzed with a fluorescence microscope. Black bars represent a 5 µm scale. 
 
 
Next, we aimed to increase the main constituent of TAGs, namely acyl-CoA and glycerol 
supplies. For acyl-CoAs, we targeted peroxisomal genes to prevent both FFA and acyl-
CoA degradation by deleting FAA2 and PXA1, encoding peroxisomal importers of FFAs 
and acyl-CoAs respectively, as well as POX1. For glycerol backbone supply, we removed 
the conversion of glycerol-3-phosphate to dihydroxyacetone phosphate by deleting GUT2, 
which encodes the enzyme responsible for this catalytic reaction. Notably, POX1 removal, 
which yielded RF09, led to a decrease of 9% in TAGs compared to RF08. Removal of 
GUT2, yielding RF10 strain, accumulated TAGs at a level of 222 mg∙gCDW-1, a slight 
increase compared to RF09, reaching similar levels as RF08 (Fig 2). However, PXA1 
removal, resulting in RF11, significantly improved TAG accumulation, reaching 254 
mg∙gCDW-1, i.e. a 14% increase in comparison to RF10. Finally, deletion of FAA2, 
resulting in RF12 had no impact on TAG levels (Fig II-5).  
 
2.3 Conclusions of Chapter II 
In this Chapter, I aimed to highlight Cas9 efficacy for genome remodeling in the context 
of engineering yeast cell factories for the production of lipid-derived products. Notably, 
through the engineering strategies applied in these two papers, we learnt that the complexity 
of the lipid metabolism, i.e. its numerous feedback regulation and balanced homeostasis 
between the different lipid classes, can be exploited to accumulate some of its compounds. 
In Paper II, we investigated the pathways involved in FFA biogenesis and showed the 
dynamics through which these metabolites can be biosynthesized. We constrained the acyl-
CoA fluxes to phospholipids in absence of fatty acid activating genes (FAA1 and FAA4) 
and ultimately generated a relatively highly engineered strain, accumulating high levels of 
FFAs and phospholipids. We exploited the Ino2/Ino4/Opi1 system which regulates the fatty 
acid and phospholipid synthesis pathways to further increase FFAs levels (149). These 
results are in agreement with previous reports where Δpah1 was shown to modulate 
phospholipids, TAGs, and FFA levels (150). While we mainly focused on FFA production 
in this study, the titers reported remained below previous reports (119, 151, 152). Notably, 
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MLM1.0 accumulates high-levels of phospholipids which could also be used as excipients 
for pharmaceutical applications (153). Additionally, we attempted to take advantage of this 
pool of phospholipids to further increase FFAs by overexpressing phospholipase B genes, 
namely PLB1, PLB2 and PLB3, but FFAs were not affected by these upregulations (Paper 
II: Figure 5) (154).  
 
For the study on enhancing TAG accumulation, the implemented push-and-pull strategy by 
overexpressing genes encoding a constitutively active version of ACC1, together the last 
two steps of TAG formation, namely PAH1 and DGA1, ultimately resulted in an 
accumulation of 12% of the dry cell biomass, more than 10-fold above the levels in the 
reference strain. Next, the disruption of several lipid droplet associated-proteins involved 
in both TAG hydrolysis, namely TGL3, TGL4, TGL5, further increased TAG levels up to 
22% of the dry cell weight (Fig. II-5). However, further disruption of the beta-oxidation 
and FFA import in the peroxisome, as well as providing more glycerol-3-phosphate 
substrate, did not affect TAGs levels. As mentioned above, FFAs are found in low quantity 
in normal conditions, as they are directly converted to acyl-CoAs by fatty acyl-CoA (114). 
While not experimentally measured, the disruption of TAG lipases might have further 
decreased the amount of FFAs available in the cell. Also, theoretically, FAA2 disruption 
would have allowed more FFAs to be converted to acyl-CoAs. Previous studies have 
reported an increase of TAG levels upon POX1 disruption, which altogether indicates that 
these disruption strategies, namely the deletion of FAA2 and POX1, could have 
significantly increase TAG levels only in the presence of TAG lipases (155).  
 
Finally, disruption of the peroxisomal fatty acyl-CoA transporter PXA1 increased TAG 
levels up to 25% of the cell dry weight. Since PXA1 encodes a transporter of fatty acyl-
CoA to the peroxisome, I speculate that deleting it ultimately increased the levels of 
available substrate for TAG biosynthesis, which ultimately points towards a potential 
limitation in cytosolic acyl-CoA availability for TAG biosynthesis.   
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Chapter III: Rewiring metabolic fluxes via 
transcriptional regulation 
 
 
 
3.1 Benchmarking CRISPR/dCas9 tools (Paper IV) 
As described in Chapter I, dCas9 variants can be used for tunable and orthogonal control 
of gene expression by sterically hindering the transcriptional activity of the RNA 
polymerase, and by fusing them with repressor and activator domains, such as the 
mammalian transcriptional repressor domain Mxi1 or with VPR. In this context, these tools 
can be harnessed for tunable expression of genes encoding enzymes of metabolic pathways 
to increase productivity. However, at the conception of the study, the metabolic engineering 
field was lacking robust orthogonal and tunable transcriptional control mechanisms, and 
metabolic engineers primarily utilized a few characterized promoters for enhancing gene 
expression. However, CRISPR/dCas9-based systems have, hitherto, not only been reported 
as robustly achieving several folds of up- or down-regulation. Graded transcriptional 
patterns can also be achieved depending on where the dCas9 complex is guided in the 
promoter region.  
 
In Paper IV, we benchmarked two dCas9-mediated systems for controlling gene 
expression of genes targeted by gRNAs in the context of metabolic engineering, i.e. 
coupled to the production of industrially relevant compounds, namely TAGs and β-carotene 
(Figure III-1). This project was a collaboration between our lab (SysBio) and Jay 
Keasling’s lab at Danmarks Tekniske Universitet (DTU), where we explored the design, 
engineering and application of CRISPR-dCas9 technology for multiplex genome 
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reprogramming of metabolic genes in yeast. The study was one of the first of its kind to 
describe the systematic use of gRNA libraries and dCas9 designs to explore CRISPR-
mediated gene expression tuning for optimizing metabolic fluxes. The first system offers 
an anhydrotetracycline (aTc) inducible expression of gRNA with dCas9 fused to regulatory 
domains. The second system combines the gRNA with RNA-stem loops facilitating the 
recruitment of scaffold-binding domains MCP and PCP fused to either VPR or Mxi, which 
ultimately allows simultaneous bi-directional and targeted gene regulation (Figure III-1) 
(156). I was involved, almost exclusively, in characterizing dCas9-VPR/Mxi applied to the 
lipid metabolism, while my colleagues at DTU were focusing on the scaffolding systems 
applied to the β-carotene pathway (70). 
 
 
 
Figure III-1. CRISPR-dCas9 tools benchmarked in β-carotene and TAG biosynthesis 
pathways. a. aTc-inducible gRNA expression vector with dCas9 fused to VPR or Mxi. b. 
Constitutive gRNA expression vector. The gRNAs are designed with an extra RNA stem-loop to 
recognize either MCP-VPR or PCP-Mxi ultimately allowing simultaneous repression and 
activation. c. β -carotene and TAG pathways. Marked in green are all the genes targeted in Paper 
IV for dCas9-based transcriptional regulation  
 
 
While throughout the study we evaluated more than 100 gRNAs targeting 14 different 
promoters, the benchmark experiment comparing the two systems was done by targeting 
two promoters involved in either fatty acid synthesis (OLE1) or the mevalonate pathway 
(HMG1) with only a single gRNA per promoter (Fig. III-1). These gRNAs were selected 
among a small selection of gRNAs targeting the respective promoters retrieved using two 
webtools (http://chopchop.cbu.uib.no, http://lp2.github.io/yeast-crispri) (Fig. III-2) (157, 
158). These tools provided a list of gRNA target sites including important information such 
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as the distance to TSS or the nucleosome occupancy (Fig. I-5). To assess the efficiency of 
these gRNAs, we coupled their respective targeted promoter to GFP and monitored the 
fluorescence level upon gRNA expression. Among the different gRNAs tested, gRNA 
OLE1 TSS -381 and gRNA HMG1 TSS -152 gave the most significant transcriptional 
regulation when coupled with the inducible and constitutive systems, respectively, and 
were subsequently selected for benchmarking these dCas9 tools.  
 
 
 
Figure III-2. Transcriptional regulation of gRNAs targeting specific promoters. a. Design of 
a small gRNA library targeting OLE1 promoter. The gRNAs were designed to cover different 
position of the targeted promoter, and characteristics of the position, such as the distance to TSS 
and the nucleosome occupancy, were also obtained. To assess their transcriptional regulatory 
effect, the targeted promoters were coupled to GFP. b. Fluorescence levels monitored using 
Biolector. Shown are the maximal fluorescence levels obtained for triplicates grown in synthetic 
media over the course of 72h.  
 
 
For the HGM1 promoter, both the constitutive and inducible system displayed around 50% 
upregulation and downregulation when coupled with their respective regulator, i.e. 
downregulation for Mxi and upregulation with VPR. For the OLE1 promoter, the inducible 
system inferred around 50% activation and repression using dCas9-VPR and dCas9-Mxi 
(Fig. III-3, Fig. III-4). Based on these only two promoters, we concluded that the inducible 
system performed slightly better than the constitutive system. To further test the fine-tuning 
applicability of the inducible system, we characterized more gRNAs targeting the OLE1 
and DGA1 promoters, two genes shown to increase TAG biosynthesis when overexpressed 
(113, 121, 159, 160).  
 
  
28 
 
 
 
Figure III-3. Transcriptional regulation from gRNAs coupled with dCas9-VPR and their 
impact on triacylglycerol production. a. Effect of different gRNAs tested for OLE1 promoter 
coupled to GFP. b. Effect of different gRNAs tested for DGA1 promoter coupled to GFP. Bar 
plots for GFP/OD represent expression relative to the control strain without any gRNA expressed. 
Engineered strains were cultivated with aTc and fluorescence levels were measured using 
Biolector. The maximum values for GFP/OD yield over the entire cultivation time were then 
extracted. Displayed are averages ± SD of maximum values of triplicates, * p value < 0.05; 
(Student’s t-test: one-tailed, two-sample equal variance) c. Over time monitoring of GFP/OD for 
OLE1p-GFP with the gRNA OLE1 TSS -381 in green and control (no gRNA expressed) in black. 
d. TAG quantification after 24 h. Strains were cultivated in 2% glucose synthetic minimal media. 
* p value < 0.05; (Student’s t-test: one-tailed, two-sample equal variance). 
 
Here, from a small library of five gRNAs per promoter designed to span over both 
promoters, gRNAs DGA1 TSS-139 (i.e. gRNA targeting DGA1 promoter at position TSS-
139, which corresponds to the distance from the TSS to the middle of the gRNA) and TSS-
58, and OLE1 TSS-381 resulted in the strongest upregulation, 2 and 2.5-fold activation, 
respectively (Fig. III-3). Notably, OLE1 TSS-29 slightly downregulated the GFP 
expression (Fig. III-3). Targeting at close vicinity to the TSS might have hindered correct 
docking of the RNA pol. II, as described in previous reports (161).  
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Finally, based on this screening, we sought to assess whether the transcriptional effect 
obtained from the gRNAs leading to highest expression levels could be translated into 
higher fluxes towards our desired compound. Single expression of OLE1 TSS-381 and 
DGA1 TSS-139 led to a 1.5-fold increase of TAG levels and 2-fold increase when 
expressed together, compared to control, i.e. no gRNA expressed (Fig. III-3).  
 
3.2 Discovering novel gene regulatory setups using targeted gRNA 
libraries (Paper V) 
In the previous sections, we rationally applied Cas9 and dCas9-based technologies to 
efficiently rewire metabolic pathways towards the production of relevant compounds. For 
dCas9, we showed that expression fine-tuning can be obtained by designing a small gRNA 
library guided to the promoter of interest. While this method has been proven efficient for 
a small set of promoters, it is challenging to apply similar screenings when targeting a large 
number of promoters at a genome-wide level. In this context, genetically encoded 
biosensors, when coupled to fluorescent output, can help enhancing the throughput by 
enabling real-time monitoring of cellular metabolism and screening of large diversified 
libraries using FACS (162) (Fig. III-4). Genome-wide approaches are particularly attractive 
in a metabolic engineering context as they allow to screen, from a population of cells, 
particular setups, e.g. gene regulation or mutations, favoring a specific phenotype. 
Conversely to our previous approaches where we focused on specific pathways, these 
approaches enable the elucidation non-obvious genes linked to the enhancement of the 
phenotype desired. As such, in Paper V we sought to exploit the high-throughput feature 
of a transcription factor-based biosensor together with the versatility and fine-tuning 
properties of CRISPR-based transcriptional regulation applied to discover novel gene 
expression fine-tuning set-ups enhancing fluxes towards precursors for oleochemical 
production. 
 
 
 
Figure III-4. Transcriptionally regulated biosensor. The transcription factor (repressor) binds 
to its target sequence (operator) in the absence of the metabolite effector (effector). The GFP 
expression is modulated based on the abundance of the effector, enabled in high levels and 
repressed otherwise. This system allows distinguishes high-producer of effectors based on the 
fluorescence levels and can ultimately be selected using FACS.  
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From the various characterized biosensors in yeast, we selected the malonyl-CoA 
responsive transcription factor FapR from Bacillus subtilis, previously characterized by 
David and colleagues (163). FapR binding sites (fapO) were integrated into a TEF1 
promoter (TEF1p) to control GFP expression as the output signal. FapR is a homodimeric 
repressor which binds to its operator (fapO) in absence of malonyl-CoA and detaches when 
bound to malonyl-CoA. Malonyl-CoA is an important precursor for various industrially 
relevant compounds, e.g. fatty-acid derived products as it is, together with acetyl-CoA, the 
main substrate of fatty-acid biosynthesis and various other products such as the bioplastic 
precursors, 3-hydroxyprionic acid (3-HP) (164).  
 
Here, while it was theoretically straight-forward to couple a genome-wide gRNA library to 
a FapR biosensor-based screening, three important questions remained concerning the 
experimental design:  
 
1. Given that there are thousands of genes whose regulation could potentially affect 
malonyl-CoA levels, and expression of each of those genes would need be fine-
tuned, which genes should be targeted? 
2. We previously observed in Paper IV that many of the gRNAs covering OLE1 and 
DGA1 promoters did not lead to any substantial change in expression level. Thus, 
how many gRNAs per promoter need to be included?  
3. How can simultaneous down- or up-regulation setups using a single system be 
achieved? 
 
We used an in silico approach based on a yeast GEM to assist on selecting which genes to 
target (question 1) (165). As briefly introduced in Chapter I, GEMs models are 
mathematical representations of the metabolic network of the cell (40, 166). They are 
constructed by integrating thousands of reactions and metabolites interacting inside the cell 
and provide a comprehensive in-depth understanding of the studied organism. One 
advantage of using GEM is the ability to perform biological predictions at the system level, 
e.g. predicting the growth rate of the studied organism or the rate of production of a 
metabolite (167). This is commonly done by Flux balance analysis (FBA) which analyze 
the flow of metabolites through a metabolic network, assuming a biological objective is 
applied in the form of maximizing (or minimizing) a certain flux at steady-state growth and 
mass balance (167). In this study (Paper V), the objective function was set to be maximized 
for cytosolic production of both acetyl-CoA and malonyl-CoA (Fig. III-5).  
 
Once the maximum specific growth rate (μmax) was established, we applied 11 suboptimal 
growth rates (0.2 to 0.8, increment: 0.05), and acetyl-CoA and malonyl-CoA production 
were maximized using FBA (Fig. III-7, Paper V: Fig. 1a-d, Table S1-2). Here, for each 
simulation, a k score that compared the flux of each reaction with the flux of the same 
reaction at maximum growth rate conditions was determined. These scores were defined as 
larger than 1 representing an increased flux compared to the μmax condition, whereas k 
scores lower than 1 show a decrease in the flux. In terms of gene expression, it was 
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arbitrarily defined that k score represented upregulation or downregulation of the gene 
expression levels and genes with a k scores between 0.549 and 1.001 were ruled out.  
 
 
 
Figure III-5. Flux-balance analysis to retrieve genes potentially enhancing malonyl-CoA 
production. Genome-scale metabolic model fundamentals where each metabolic reaction and 
its constituents are mathematically represented in a global model. Here, we applied FBA 
maximizing the production of malonyl-CoA as the objective function of the model. Fluxes towards 
malonyl-CoA are computationally evaluated at different growth rates and a list of genes 
potentially contributing to enhancing malonyl-CoA production is retrieved. A target score for 
upregulation or downregulation is associated to each gene as a proxy for fine-tuning. Here, for 
all α's and all reactions, the scoring is defined as the average of the fluxα over fluxWT 
 
 
These in silico analyses ultimately scored genes that are expected to affect fluxes towards 
the production of acetyl-CoA and malonyl-CoA at different growth rates, and ultimately 
reduced the number of genes to target to only 168 genes, with 70 genes targeted for 
upregulation, 80 for downregulation, and 18 found to be either upregulation or 
downregulation targets depending on the carbon source (Paper V: Table S2) (Fig. III-5).  
 
To answer the second and third questions, we described in the previous section how the 
constitutive CRISPR-dCas9 system could potentially enable both activation and 
downregulation with the help of RNA-stem loops fused to the gRNA. However, we 
observed that this system was underperforming compared to the inducible system. 
Furthermore, gRNAs targeting the OLE1 promoter in the close vicinity to the TSS led to a 
downregulating effect even when guiding dCas9-VPR (OLE1 TSS -29) (Fig. III-3). Thus, 
to both counteract the uncertainties that influence gRNA regulatory efficiency and reach 
optimal transcriptional interference (up- or downregulation), we designed up to 21 gRNAs 
covering each targeted gene, including up to five adjacent to their respective TSS. This 
design yielded to a library of 3194 gRNAs (Paper V: Table S2).  
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Figure III-6. DBTL cycle applied to the study. Design. The gene scores are obtained by FBA, 
a gRNA library of 3194 gRNAs is designed to target these genes. Build. The gRNA library is 
cloned into a dCas9-VPR plasmid and transformed into a yeast strain expressing the FapR-
based malonyl-CoA biosensor. Test. Multiple rounds of fluorescence-based sorting and NGS are 
applied to retrieve the promising gRNAs, i.e. gRNAs potentially enhancing the flux towards 
malonyl-CoA. Then, the enriched gRNAs are assessed on their efficiency to improve 3-HP 
production as well as transcriptional regulation by coupling their targeted promoter to GFP. 
Learn. Based on the 3-HP and transcriptional regulation data, we can elucidate the effect of the 
selected gRNAs on yeast metabolism.  
 
The gRNA library was subsequently cloned into the inducible dCas9-VPR plasmid and 
inserted into yeast expressing both FapR constitutively and ACC1** under control of the 
HXT7 promoter (CEN.PK-11C + HXT7p-ACC1** + FapR-based malonyl-CoA biosensor). 
ACC1** was chosen in order to channel potential increases of the acetyl-CoA pool towards 
the malonyl-CoA pool, and thus activating the malonyl-CoA biosensor response. The yeast 
library was consecutively sorted using FACS over three days using two different 
fluorescence gates (Fig. III-7). Next-generation sequencing (NGS) was performed at each 
stage and the gRNA distribution in the population was determined. From this analysis, we 
subsequently selected the gRNAs that were most significantly enriched throughout the 
different sorting steps, and ultimately, assess their performance on both their transcriptional 
regulation, i.e. fine-tuning properties on their respective targeted promoters coupled to 
GFP, and enhancing fluxes towards malonyl-CoA pools, through quantification of 
malonyl-CoA-derived product titers, in form of 3-HP (Fig. III-6).  
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Figure III-7. Three-day sorting strategy of the yeast library. a. After 7 h of culture, the yeast 
library was subsequently sorted using two different gates, one for medium fluorescence, P2, and 
one for high fluorescence, P3. The yeast strains without the library (empty plasmid) in the left 
show few cells on P2 and P3. b. Three-day sorting using the two gates, except for P21-P2+P3 
where P21-P2 and P21-P3 were accidentally mixed together. Each pie chart represents the gRNA 
distribution after the sorting. The colored lines represent the day of sorting: black for day 0; red 
for day 1; blue for day 2; and green for day 3. c. Log2 fold-change gRNAs over the initial library 
(pre-culture). Shown in red are the most enriched gRNAs that were subsequently tested for 3-
HP.  
 
From the different sorting schemes, we selected 49 gRNAs, targeting a total of 46 genes, 
that were enriched after three rounds We subsequently validated their efficacy to enhance 
malonyl-CoA levels by evaluating their expression on the production of 3-HP. It can be 
obtained by expressing the bifunctional malonyl-CoA reductase Mcr from Chloroflexus 
aurantiacus which directly catalyzes the conversion from malonyl-CoA to 3-HP in a two-
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step reaction (168). Expression of Mcr formed a direct metabolic pull likely converting any 
(even temporary) increase in malonyl-CoA into 3-HP accumulation over time. Here, among 
all gRNAs selected, only a few ultimately increased the overall 3-HP yield by more than 
10% (Fig. III-8). We selected 14 of these genes and coupled their respective promoters to 
GFP expression (Fig. III-8, Paper V: Fig. S4, Table S5).  
 
Analysis of the interesting gRNAs 
 
We observed that most efficient gRNAs target genes whose corresponding enzymes use 
NAD+ as co-factor, e.g. cytoplasmic aldehyde dehydrogenase Ald2, glyceraldehyde-3-
phosphate dehydrogenase Tdh2, or, expectedly, genes located upstream of malonyl-CoA 
pathway, e.g. Acs2, Ald2, Pdx1 (Fig. III-8; Paper V: Fig 2c, Table S4). The highest 
increase in 3-HP yield (36% increase) was achieved by a gRNA targeting the gene encoding 
adenylate kinase 1, ADK1 #15 (TSS -761), which also showed a downregulating effect on 
the activity of the promoter coupled to GFP (Fig. III-8). Here, if regulating ADK1 causally 
impacts 3-HP, I speculate that this regulation might have led to (i) a decreased availability 
of ADP, an important metabolite that positively regulates Acc1 regulator Snf1, and (ii) an 
increased level of ATP, which is used in the biosynthesis of malonyl-CoA from acetyl-CoA 
(169–171). Interestingly, the gRNA also binds downstream of HTA1, which encodes one 
of the main histone proteins involved in the chromatin structure. This binding might have 
reduced HTA1 mRNA levels by blocking RNA polymerase II and thus potentially changed 
chromatin structures and consequently the expression levels of other genes. Targeting 
ALD2 gRNA #1 (TSS -241) increased 3-HP yield by 27% compared to the control, and 
also showed a significant increase in GFP (Fig. III-8). This gene is repressed in the glucose 
phase (172), and we speculate that in a context where NAD+-dependent enzymes seem to 
be favored for increased fluxes towards malonyl-CoA, de-repressing it, eventually 
benefited 3-HP production. ARO4 #18 (TSS -641) expression led to a 22% increase in 3-
HP yields but, surprisingly, did not influence ARO4 transcriptional levels (Fig. III-8). As 
with ADK1 #15, we noticed that ARO4 #18 (TSS -641) binds closer to the adjacent gene, 
SPO23 (YBR250W). As such, the effect on the SPO23 promoter coupled to GFP led to a 
significant upregulation (Fig. III-8). SPO23 has not yet been characterized which makes it 
challenging to speculate on the underlying reasons behind the increase in 3-HP yields. 
However, Tevzadze and colleagues highlighted a close interaction between Spo23 and 
Spo1, a meiotic PI-specific phospholipase B, which could indicate a link with fatty acid 
turnover (173).  
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Figure III-8. Effect of the enriched gRNAs on enhancing fluxes towards malonyl-CoA. a. 
Shown are the yields increased by more than 15% the total 3-HP levels normalized to OD and 
control (no gRNA expressed). Values were obtained in triplicates grown in defined minimal 
medium with 20 g∙L-1 glucose and cultures were sampled after 72 h. Displayed are averages ± 
SD. ** p value < 0.01; * p value < 0.05; (Student’s t-test: one-tailed, two-sample equal variance). 
d. Influence of different gRNAs on the activity of the respective target promoter. Shown are TKL2 
#7 (TSS -147); and ALD2 #1 (TSS - 241), #7 (TSS -241), #9 (TSS -251), and #12 (TSS -192). b. 
Mean fluorescence intensities (GFP/OD) were obtained from three biological replicates ± S.D. 
monitored with a BioLector. 
 
 
Finally, we also identified new candidate genes to increase 3-HP production such as genes 
involved in the processing of precursors upstream of malonyl-CoA, e.g. TKL2 encoding 
transketolase, and PDX1 encoding a subunit of the pyruvate decarboxylase complex as well 
as AHP1 encoding a peroxiredoxin that protects against oxidative stress (Fig. III-8). 
Notably, PDX1 #17 (TSS-504) shows a downregulating effect on PDX1 promoter and this 
effect might have enhanced the flux cytosolic conversion of pyruvate to acetyl-CoA instead 
of the NAD+ consuming mitochondrial one (Fig. III-8) (174).  
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3.3 Conclusions of Chapter III 
In Chapter III, we explored dCas9-based technologies for fine-tuning of biosynthetic 
pathways. As previously mentioned, achieving correct expression of the genes involved in 
the studied pathway as well as determining which genes to reprogram remain currently 
challenging to achieve with traditional engineering strategies. In Paper IV, based on 
multiple gRNAs tested, we established dCas9-VPR as a robust tool for rewiring metabolic 
fluxes in yeast, among the different CRISPR-dCas9 tools. This was concluded by, first, 
monitoring the fluorescence levels of the targeted promoter to GFP upon the gRNA 
expression, and by quantifying TAG levels (as these gRNAs were targeting genes involved 
in lipid biogenesis pathways).  
 
Then, in Paper V, we sought to apply the same methodology at a larger scale. We 
established a framework based on GEM simulations for predicting key genes that 
potentially favor the production of the endogenous metabolites and exploited the versatility 
of dCas9-VPR for fine-tuning gene expression coupled with an intracellular biosensor for 
selecting high-producing cells. Here, our in silico constraint-based modeling approach 
predicted a specific set of 168 genes whose regulation potentially impact the production of 
malonyl-CoA. Then, combining a gRNA library targeting these genes and a malonyl-CoA 
responsive intracellular biosensor in yeast ultimately enabled to retrieve optimal gene 
expression of both known and novel genes contributing to enhancing the flux towards 
cytosolic malonyl-CoA. However, while we observed that 3-HP production was improved 
upon fine-tuning genes involved in providing malonyl-CoA precursor, co-factor supply, as 
well as chromatin remodeling, many of the selected gRNAs were not influencing 3-HP 
levels. This indicates that either these gRNAs might still increase malonyl-CoA levels but 
not sufficiently to be converted to 3-HP, or that the selection parameters I chose for the 
study were not optimal. Another possibility could come from the discrepancy between the 
fluorescence sorting performed approximately at the glucose phase and the 3-HP sampling, 
performed at 72 h. Thus, enriched gRNAs that marginally enhance malonyl-CoA during 
the glucose phase might not be enough to reach a significant increase in 3-HP yields.  
 
While applied for malonyl-CoA, the same approach can be could in theory be applied for 
other metabolic engineering studies. Thus, I developed an R shiny app that allows users to 
easily choose a metabolite to optimize in yeast. Once the metabolite selected, the tool 
generates a list of suggested genes to regulate with a detailed list of gRNA targeting them 
(hosted at https://raphdl.shinyapps.io/crispri-gem/).  
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Chapter IV: Expanding the CRISPR repertoire - 
Developing new tools to accelerate strain engineering 
 
 
 
4.1 Increasing the targeting range through multiplexing (Paper VI)  
When conceptualizing Paper VI in early 2016, the research landscape that applied 
multiplexing features for yeast strain design remained at its infancy (175, 176). Thus, we 
aspired to contribute to the yeast scientific community by developing a multiplexing tool 
for both genome engineering and gene regulation.  
 
CRISPR-associated endonuclease Csy4. 
As described in Chapter I, the type I CRISPR-system is defined by having the crRNA 
guiding a cascade complex made of several proteins to target invading viral DNA (Box 1). 
The interference is then performed by the Cas3 subunit. In Pseudomonas aeruginosa, the 
cascade complex is composed of Csy enzymes, with Csy4 binding and processing the pre-
crRNA in crRNAs (Fig. IV-1). This endoribonuclease has been shown to have a high 
degree of substrate binding towards a 28 nucleotide RNA stem-loop (5’- 
GUUCACTGCCGTATAGGCAGCUAAGAAA-3’) and cleaves after the guanine at 
position 20 downstream (underlined in bold) (Haurwitz et al. 2010, Haurwitz et al. 2012). 
Additionally, previous structural studies have revealed the ability of Csy4 to discriminate 
its crRNA from other cellular RNAs. Altogether, Csy4 is an ideal candidate for attempting 
to carry out multiplexing experiments (Fig. IV-1).  
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Figure IV-1. Utilization of elements from Type I CRISPR-systems for genome editing and 
gene regulation. a. Overview of Type I CRISPR-system. The csy complex is usually composed 
of several csy genes, including csy4 (in yellow). Csy4 processes the CRISPR array to generate 
several crRNA which will then be used for the interference step against phages. b. Harnessing 
Type I Csy4 from P. aeruginosa for gRNA multiplexing. 
 
Genome editing and gene interference applications in S. cerevisiae. 
We first sought to characterize the ability to perform multiple gene knockouts by 
simultaneously generating gRNAs from a single transcript using Csy4 in yeast. Thus, 
starting from a strain constitutively expressing Cas9 (IMX581: MATa MAL2‐8c SUC2 
ura3‐52 can1::PTEF1-cas9), we constructed and genomically integrated the gene encoding 
Csy4 (with a nuclear localization signal) expressed under control of TEF1p.  
 
Next, we designed an array of four gRNAs in a row, targeting genes involved in the fatty 
acid metabolism: FAA1, FAA4, POX1, and TES1, interspaced by the Csy4 28nt recognition 
sequence (Fig. IV-2). These gRNAs were previously evaluated in other projects (e.g. Paper 
II) thus their high-efficiency was known. The gRNAs transcript was expressed under the 
constitutive RNA Pol. III promoter, SNR52p, from a multi-copy 2µ plasmid. The plasmid 
was transformed along with linear repair DNA fragments matching the flanking regions of 
the targeted genes, causing a deletion of the genes. Expression of Csy4 yielded close to 
100% efficiency of quadruple knockouts, whereas in absence of Csy4 only double 
knockouts were detected. These results confirmed the ability to use Csy4 for multiplexed 
knockouts (Fig. IV-2). Notably, the reasons behind achieving a double knockout even in 
absence of Csy4 could potentially be the instability of the scaffold due to the many 
repetitive elements (28nt + 79nt gRNA scaffold) coupled with the fact that the gRNAs 
being expressed in a multi-copy plasmid and under a constitutive promoter might have 
generated partial transcripts. 
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Figure IV-2. Multiplexing genome editing using Csy4. a. Multiplexing of four gRNAs targeting 
FAA1, FAA4, POX1, and TES1, for gene knockouts. b. Expression of Csy4 allows near-perfect 
quadruple knockout (in 24 colonies tested). c. Multiplexing of three gRNAs targeting HMG1p, 
OLE1p, and ACS1p, for gene regulation using dCas9-VPR. d. Fluorescence quantification at 
OD600 = 8. Red dotted line defines levels of GFP when no gRNA is expressed. Pink: HMG1p-
GFP; Turquoise: OLE1p-GFP; Yellow: ACS1p-GFP 
 
We next sought to assess the capacity of our platform for efficient transcriptional regulation 
applications. As with the knockout experiment, we designed an array of three gRNAs, 
which have been previously characterized (Paper IV), interspaced by the 28 nt sequence 
and expressed them from a single copy plasmid under control of a tetracycline-inducible 
RPR1 promoter (70, 157). The multiplexed and Csy4-processed gRNAs reached the same 
level of transcriptional regulation as to when the particular gRNA was expressed alone 
POLE1 and PHMG1 (Fig. IV-2, Fig. IV-3). For ACS1, the processed gRNA-transcript reached 
almost the same level as the positive control in the presence of Csy4 (Fig. IV-3). Here, we 
notice that the in absence of Csy4, GFP levels were similar to the control (empty plasmid). 
This indicates the importance of controlling the expression of gRNAs to produce significant 
interference, i.e. using a single-copy plasmid might prevent the generation of partial 
transcripts interfering with the experiment, as we saw in with the genome engineering 
experiments. 
 
In conclusion, we showed that Csy4 specific endoribonuclease activity can efficiently be 
utilized for multiplexing of CRISPR-mediated gene deletion and interference in S. 
cerevisiae.  
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Figure IV-3 Detailed transcriptional regulation with and without Csy4. Shown here are the 
GFP in function of OD for one array processed (or not) by Csy4. In black: empty plasmid; grey: 
unique gRNA; light blue: array of gRNAs without csy4 expression; blue: gRNA array processed 
by Csy4. 
 
4.2 Exploiting promiscuous on-target specificity (Paper VII) 
In the previous section, we showed that processing an array of gRNAs in a row allowed to 
target multiple targets at once. Metabolic engineering of microbial cell factories usually 
requires targeting genes within the same pathway. One example is targeting multiple genes 
encoding enzymes carrying the same catalytic function, so-called paralogs, e.g. FAA1 and 
FAA4 for preventing FFA degradation, or TGL3, TGL4 and TGL5 for TAG degradation 
(Paper II, Paper III). These paralogs are usually derived from genome or gene duplication 
and thus show remarkable sequence similarities. Based on this feature, we sought to exploit 
that feature to accelerate strain design, i.e. exploiting promiscuous on-target idiosyncrasies 
of certain gRNAs for multiplexed engineering. These gRNAs, that we coined “promiscuous 
gRNAs”, eventually would allow minimizing the use of gRNAs in applications where 
editing multiple genes simultaneously is desirable (see previous sections).  
 
 
Figure IV-4. Graphical representation of a promiscuous gRNA. 
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We designed a computational tool to retrieve and explore promiscuous gRNAs. The tool 
was written in R and is made available on GitHub 
(https://github.com/gattofrancesco/pgRNA). The algorithm was built to use a genome 
sequence or a list of genes as input and extract all gRNAs by locating the PAM sequence 
in the target region (Fig. IV-5). An option to filter poor quality gRNAs, such as gRNAs 
with repetitive nucleotides, is possible by imposing minimal %GC content. Each gRNA is 
then aligned back to all the original targets, and any gRNA with several matches is defined 
as promiscuous gRNA. The probability for a gRNA to find new matches can be increased 
by allowing mismatches in the sequence. Then, the hits are analyzed, and a list of the most 
promising promiscuous gRNAs is generated (Fig. IV-5). 
 
 
 
Figure IV-5. Workflow of the promiscuous gRNA tool.  
 
 
We chose to apply our tool to identify promiscuous gRNAs targeting multiple sites in the 
S. cerevisiae genome and experimentally validate some of them (Fig. IV-6, Fig. IV-7). For 
the whole genome, 801,648 individual gRNAs were retrieved for all sixteen nuclear 
chromosome sequences, with the most promiscuous gRNA 
(“GCAAGGATTGATAATGTAAT”) binding a total of 148 times. The promising 
promiscuous gRNAs expectedly showed a significant number of hits in repetitive elements 
such as Ty retrotransposons and tRNA regions. While I have unsuccessfully tried to 
experimentally validate these highly promiscuous gRNAs with the aim of removing these 
repetitive elements, in Paper VII we exclusively targeted coding sequences.  
 
 
Figure IV-6. Promiscuous gRNAs for S. cerevisiae’s whole genome.  
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We next set out to experimentally validate several predicted promiscuous gRNAs. From 
the initial extracted gRNAs, only 1% had two or more targets. From this list, we limited 
our search to promiscuous gRNAs targeting 2 genes in the lipid metabolism and tested their 
efficacy via gene deletion (Fig. IV-7). We selected in a first experiment, a promiscuous 
gRNA targeting FAA1 and FAA4, and in a second experiment, a promiscuous gRNA PLB1 
and PLB2 (Fig. IV-7). Finally, correct ratio of successful deletion reached 100% for both 
FAA1/4 and PLB1/2 experiments (Fig. IV-7). In conclusion, this study proposes a 
computational approach to exploit promiscuous on-targeting effects of gRNAs to consent 
multiplexed genome editing in a time and cost-effective fashion. 
 
 
 
 
Figure IV-7. Application of promiscuous gRNAs for genome editing in S. cerevisiae. a. 
Computational output of the algorithm when taking lipid metabolic genes as input. b. Two 
promiscuous gRNAs tested, one targeting both FAA1 and FAA4, the other targeting both PLB1 
and PLB2. Along with the promiscuous gRNA, the strains were co-transformed with repair 
fragments matching the flanking regions of the genes targeted. c. Agarose gel showing colony 
PCRs. Correct deletions for FAA1 and FAA4 showed bands at 709 and 647 bp, respectively. For 
PLB1 and PLB2, correct deletion showed a band 2705bp obtained by NHEJ, while the control 
(CTRL) shows a band at 5615bp.  
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4.3 Cas12 and Cas13 
Besides Csy4, I, together with colleagues, have attempted to characterize other types of 
CRISPR-systems in yeast, namely Cas12 and Cas13 (Fig. IV-8).  
 
 
 
Figure IV-8. Cas12a (Cpf1) and Cas13 features. a. b. Cas13 performs targeted cleavage of an 
ssRNA substrate. dCas13-ADAR RNA base editing converts A to I (read as G). dCas13-
APOBEC RNA base editing converts C to U. 
 
 
Cas12a 
Cas12a, initially known as Cpf1, is an ortholog of Cas9 that offers several attractive 
features: (i) it possesses an RNA processing domain that enables CRISPR array processing 
into multiple crRNAs (74); (ii) its resulting DNA cleavage leaves a 5′ overhang instead of 
a blunt-end cleavage for Cas9 (73); (iii) it has target specificity superior to Cas9 (177); (iv) 
it recognizes a T-rich PAM; and (v) it is slightly smaller than Cas9, thus more attractive for 
clinical applications (73) (Fig IV-8). Following the same approach as the one employed for 
Csy4, I aimed to apply this system for genome engineering and gene regulation in S. 
cerevisiae. At the time of conceptualizing the project, the Cas12a from Francisca novocida 
(FnCpf1) had been described to cut plasmid DNA integration in E. coli (73), and further 
characterization of its dual-nuclease (RNA and DNA) characteristic had been described 
from Charpentier’s lab (74). Based on these two studies, I aimed to characterize the ability 
to generate multiplexed gene knockouts by attempting to remove FAA1 and FAA4, as well 
as gene activation by targeting OLE1. While I have been successful at removing FAA1, 
multiplexed removal of both FAA1 and FAA4 turned out to be more problematic (Fig. IV-
9). Also, my attempts to characterize a dead-Cpf1-VPR did not yield any transcriptional 
regulation when targeting the OLE1 promoter (data not shown).  
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Finally, over the course of my efforts, Świat and colleagues successfully characterized 
FnCpf1 for multiplexed gene editing in yeast (up to four gene deletions) (178), and more 
recently, Liao and colleagues applied dCas12 for gene activation (179).  
 
 
 
Figure IV-9. Cas12a (Cpf1) proof-of-concept for gene knockout. Colony PCRs for the deletion 
of FAA1. Bands shown at 709bp represents correct deletion, while the band at 2900bp for colony 
7 shows wild-type genotype.  
 
 
Cas13b 
Cas13 systems, initially known as C2c2, have recently been developed for precise 
transcriptome engineering (180, 181). The Cas13 RNA targeting nuclease from Prevotella 
sp. (Cas13b) is a single-effector nuclease specialized against RNA phages (Fig. IV-8) 
(182). A catalytically inactive mutant (dCas13) has, in the recent years, been developed for 
RNA single-base editing via fusing it to deaminase enzymes (183). In general, deaminases 
irreversibly catalyze the conversion of the nucleotide NH2 group to a ketone leading to a 
base conversion. The only published example of adenine deaminase applied in RNA editing 
technologies is ADAR2 which converts adenine to inosine (A to I). Inosine is read as 
guanine during translation. For correct base-editing, a mismatch in the gRNA is required 
to selectively deaminate the single mismatched nucleotide. At the time of conceptualizing 
this project, RNA base editing was limited to adenine to inosine transitions, but has since 
July 2019 been extended to cytidine to uridine conversion (C to U) (184). Thus, we sought 
to characterize ADAR2 A to I RNA editing in yeast. Additionally, we attempted to develop 
a C to U RNA editing system by fusing dCas13b to the cytidine deaminase APOBEC1 (Fig. 
III-8). To validate both systems we generated two mutated forms of GFP with an early stop 
codon aimed to be reverted to the original codon by either dCas13-ADAR through an A to 
I edit, or dCas13-APOBEC through C to U (Fig. IV-10). Unfortunately, while we tested 
several gRNAs (seven) with various spacer lengths for each system, none of them were 
able to restore GFP (Fig. IV-10).  
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Figure IV-10. System for testing base edits of dCas13-ADAR and APOBEC. a. The red 
asterisk in GFP represents the early stop codon mutation aimed to be reverted to the original 
codon by either ADAR through an A to I edit, or APOBEC through an C to U edit. b. Flow-
cytometry of cells expressing the gRNAs tested. In gRNA histograms, blue represents 
fluorescence with an empty plasmid and red with the gRNA expressed. For the control histogram, 
red is the positive control, i.e. unmutated GFP expression. 
 
Notably, during our work in the lab, Jing and colleagues reported the successful 
implementation of an ADAR base editor in Schizosaccharomyces pombe, using a dCas13 
from Leptotrichia wadei (dCas13a-ADAR), with an editing efficiency reaching up to six 
percent (185). Here, one can speculate that base-editing in our systems possibly existed but 
not to the extent to be significantly observed in our flow-cytometer experiment. Here, NGS 
on the targeted sequence could have provide more insight to this question. Therefore, if 
base-editing occurs using in our system, it requires further optimization. 
 
4.4 Conclusions of Chapter IV 
In this chapter, I sought to highlight the diversity and versatility offered by CRISPR 
technologies. The constant invasions of phages and mobile genetic elements has led to the 
evolution of prokaryotes and archaea with the adaptive and heritable CRISPR system, 
ultimately yielding a plethora of diverse elements that can be exploited for genetic 
engineering (186). For example, in Paper VI, we harnessed the Type-I Csy4 from P. 
aeruginosa for multiplexed genome engineering and transcriptional regulation via 
processing an RNA transcript into multiple gRNAs. For genome editing, we performed a 
quadruple deletion with near-perfect efficiency out of 24 colonies tested, and for gene 
regulation, we showed that a Csy4-processed array of three gRNAs could reach similar 
transcriptional regulation levels as individually expressed gRNAs. Csy4 has not been, to 
date, extensively applied in yeast. Possible reasons might be due to the existence of self-
cleaving elements, which removes the need of heterologous genes for multiplexing. 
However, Ferry and colleagues, for example, constructed a switchable gRNA by 
connecting the crRNA sequence with the 28 nt Csy4 target sequence, ultimately locking 
the gRNA and preventing it from binding to the genome without Csy4 processing (187). 
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Also, McCarthy and colleagues recently expanded our work (Paper VI) by achieving 
multiplexing of 12 gRNAs under an RNA pol. II promoter, drastically facilitating the 
cloning procedure (188).  
 
Additionally, we tried to characterize Cas9 orthologs in yeast, namely Cas12a and Cas13b, 
for genome engineering and gene regulation, and transcriptome engineering, respectively. 
While Cas12a showed promising results in terms of gene deletion, I have failed to achieve 
both array processing of two gRNAs in a row (gRNAFAA1 followed by gRNAFAA4) and 
transcriptional regulation (Fig. IV-9). Notably, the direct repeats I selected for FAA1/4 were 
36 nt long, which Świat and colleagues have reported lower efficiency of RNA processing 
by Cas12a in comparison to 19 nt repeats (19-37% vs. 100%) (178). This result, alongside 
with selecting an intrinsically poorly efficient gRNA, could have been the reasons of the 
unsuccessful multiplexing (178). For base-editing using dCas13 CRISPR-systems, based 
on the study on S. pombe from Jing and dCas13a-ADAR where they achieved up to six 
percent success rate of base-editing, future approaches could take into consideration 
focusing on dCas13a instead of dCas13b (185). Additionally, restoring GFP via base-
editing might not be the appropriate system when the rate of base-editing is extremely low. 
Here, NGS would give a better readout, as the expected base replacement would be 
quantifiable by analyzing the reads.  
 
Most of the currently available bioinformatics tools for designing gRNAs only suggest 
gRNAs uniquely targeting in the host genome, i.e. without any off-targets. In Paper VII, 
we designed a bioinformatic tool opposite to this paradigm, i.e. a tool exploiting the off‐
targeting of gRNAs for accelerating genome engineering. As a side note, this project was 
conceptualized after noticing the extensive number of deletions needed in metabolic 
engineering, and how often the engineering strategies required targeting paralogs from the 
same pathway, e.g. PLB1, PLB2, PLB3, or FAA1, FAA4, and I have since applied it for 
studies in human cell lines (189). There are other circumstances in which off‐targeting 
might be desirable, e.g. finding synthetic lethality in cancer (190), or minimizing a genome 
(discussed in Chapter V) (191). Based on the current number of citations, our promiscuous 
gRNA tool has not been extensively utilized by other researchers. One reason might be the 
difficulty to use it and its low speed when targeting complex living organisms. Thus, I have 
decided to facilitate access to the information of existing promiscuous gRNA by developing 
an R Shiny application that contains a database of promiscuous gRNA from several 
organisms. This will remove the need to run our existing framework in R and hopefully 
allow more people to exploit promiscuous gRNA in their studies.  
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Chapter V: Conclusions & Perspectives  
 
 
 
5.1 Future engineering strategies for the production of oleochemicals  
Throughout the thesis, I have attempted to emphasize the technological diversity provided 
by CRISPR and apply it in the context of building efficient yeast cell factories for the 
production of oleochemicals, namely TAGs and FFAs in Chapter II, and 3-HP in Chapter 
III. In Paper II, we disrupted several metabolic fluxes, namely reactions involved in the 
fatty acid oxidation, the production of storage lipids, and the conversion of FFAs to fatty 
acyl-CoA, which, in the end, constrained the lipid metabolic network to its main 
components. The combined deletions minimized the complexity of the lipid metabolic 
network by disrupting many regulation mechanisms. The resulting strain, MLM1.0, 
efficiently redirected fatty acid fluxes toward phospholipids and yielded a strain 
accumulating high levels of both FFAs and phospholipids. While the FFA titers achieved 
in MLM1.0 remained below previous reports, it is worth to mention that the strain does not 
carry any additional overexpression of genes. It would confer an advantage when 
expressing heterologous pathways that further convert the FFAs to other valuable products, 
compared to the superior strains reported, as MLM1.0 could have more proteome mass 
available to allocate (119, 151, 152). For example, Leber and colleagues reported 2.2 g∙L-1 
of FFAs from an engineered strain designed to force fluxes towards TAG synthesis and 
hydrolysis, namely overexpression of DGA1 and TGL3, in a FAA1, FAA4, FAT1 and FAA2, 
POX1, and PXA1 deletion strain (152). Our attempts to carry out similar strategy for 
MLM1.0, i.e. overexpressing endogenous phospholipases B, did not further increase the 
FFA levels. Notably, the expression of a thioesterase (‘TesA) from E. coli significantly 
improved FFA levels in MLM1.0 strain (Paper V: Fig. 5B). Thus, future strategies would 
need to elucidate ways to harness this accumulated pool of phospholipids, e.g. via the 
overexpression of efficient heterologous phospholipases, and fine-tuning of the flux from 
PA to PLs, as well as the acyl-CoA pool, e.g. via the overexpression of GPAT and LPAT 
genes (192). Notably, Yu and colleagues have recently achieved the highest FFA titers 
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reported by microbial fermentation (33.4g∙L-1 by fed-batch fermentation) through extensive 
metabolic rewiring and adaptive laboratory evolution strategies (151). Sequential alteration 
of the metabolism was achieved by (i) the integration of heterologous pathways to produce 
FFAs, (ii) the deletion of the pyruvate decarboxylase encoding genes (PDC1/5/6) to disrupt 
the ethanol production from pyruvate, (iii) proper balancing of NADPH, ATP, and acetyl-
CoA, and (iv) ultimately a directed laboratory evolution to improve cell growth on glucose. 
Because their strategy to achieve high titers extensively focus on pathways upstream acetyl-
CoA, there is compatibility with our strategy developed in Paper II, where targeted genes 
were located downstream acetyl-CoA (Fig. V-1).  
  
 
 
Figure V-1. Suggestions for future strategies for improving FFA production. Strategies 
inspired from the work presented in Paper II, combined with Yu et al. 2018 (151), and Wei et al. 
2018 (192) reports. In blue: endogenous enzymes; purple: heterologous enzymes. Green arrow 
represents upregulated genes; red arrows: downregulated genes; crossed & dashed arrow: 
deleted genes; Pgi1: glucose-6-phosphate isomerase; Zwf1: glucose-6-phosphate 1-
dehydrogenase; Pyk1*: mutated pyruvate kinase; Pdc: pyruvate decarboxylase; Mpcox: 
mitochondrial pyruvate carrier; RtCit1: citrate synthase from Rhodosporidium toruloides; Cit1: 
citrate synthase; mPyc1: mitochondrial pyruvate carboxylase 1; Idh2: mitochondrial isocitrate 
dehydrogenase 2; Yhm2: citrate/oxoglutarate carrier protein; Idp2: cytoplasmic isocitrate 
dehydrogenase; AnAcl: ATP citrate lyase from Aspergillus nidulans; Acc1: acetyl-CoA 
carboxylase 1; RtFas: fatty acid synthase from R. toruloides; Opi1: transcriptional repressor Opi1; 
‘TesA: acyl-CoA thioesterase A from E. coli; Cds1: phosphatidate cytidylyltransferase; Pah1: 
phosphatidic acid phosphohydrolase 1; Pox1: acyl-coenzyme A oxidase; Pxa1: peroxisomal 
long-chain fatty acid import protein 2; TcGpat4: glycerol-3-phosphate acyltransferase 4 from 
Theobroma cacao; LcPat4: lysophosphatidyl acyltransferase 4 from Theobroma cacao; ?: 
heterologous enzyme(s) harnessing PL pools, e.g. phospholipase B. TCA: tricarboxylic acid 
cycla; PLs: Phospholipids; PPP: pentose phosphate pathway; β: β-oxidation.  
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In Paper II, despite our efforts to engineer to S. cerevisiae to accumulate large amount of 
TAGs and ultimately achieving the highest titers reported so far, oleaginous yeasts, such as 
Lipomyces starkeyi, R. toruloides, Y. lipolytica, largely outperform S. cerevisiae (193). 
However, while we carried out many deletions, many of them turned out to have no effect 
on TAG levels (in a strain accumulating high levels of TAGs). Indeed, the main effects 
massively increasing TAGs levels were (i) the push-and-pull strategy, inspired from 
Runguphan and Keasling (121), where fatty-acid and TAG biosyntheses were upregulated 
by overexpressing ACC1**, and DGA1 + PAH1, respectively; and (ii) disruption of the 
main TAG hydrolysis genes, namely TGL3, TGL4, and TGL4, whose deletions were 
previously reported by Ploier and colleagues (194). Notably, among the different deletions 
carried out in the study, processing the acyl-CoA pool by deleting PXA1, which encodes a 
fatty acyl-CoA peroxisomal transporter, significantly increased the TAG pools. This result, 
together with the introduction of TesA in Paper II whose expression significantly 
increased FFA pools, might indicate a surplus of acyl-CoAs available for further 
processing. Future strategies to reach levels approximate to oleaginous yeasts would 
require extensive additional engineering, in addition to those mentioned for FFAs as they 
are compatible with TAGs production (Fig. V-1) (151, 192). For example, Teixeira and 
colleagues offered an approach to improve TAG levels based on modifying the structural 
mechanisms of the LD. In their study, they obtained a 138% increase from strain RF07 
strain by overexpressing the human and fungal perilipins (PLIN3 and MlPLP1) which are 
involved in LD biogenesis, and deleting ERD1 which encodes a predicted membrane 
protein required for lumenal ER protein retention (118). 
 
5.2 The golden age of genetic engineering 
Despite its only recent discovery, CRISPR/Cas9 technology has already been enhanced to 
the point of fulfilling most of the genome editing and gene regulation currently needed, 
ranging from the ability to perform multiple gene insertions, gene knockouts and the 
generation of combinatorial libraries to advanced fine-tuning of biosynthetic pathways. 
Thus, the industrial biotechnology field using metabolically engineered microbial cell 
factories has progressively been shifting from studies with few genetic modifications to 
highly complex engineered strains (188, 195–198). CRISPR has become an established tool 
for these microbial cell factories, and the field is observing more and more complex 
organisms being successfully engineered with this technology (199, 200). In Chapter II, 
CRISPR/Cas9 enabled us to rapidly construct strains, with our most engineered strain 
reaching eleven modifications (154). This technology, overall, sensibly increases the pace 
of the DBLT, as the building phase is empirically the longest phase (Fig. I-2). One can 
speculate that complete biosynthesis of complex compounds such as secondary metabolites 
will be more frequently reported using CRISPR technology to either integrate these 
complex pathways into a well-characterized organism or, directly genetically engineer the 
host organism. Decision on these two options, will, most likely, be based on the extent a 
model organism can be engineered to reach the desired function. The orthogonality of Cas 
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enzymes is relatively well established, and the main barrier for engineering these complex 
organisms remains the engineering efficiency. While the highly efficient HR machinery in 
S. cerevisiae has allowed CRISPR tools to be easily applied and developed, the advent of 
newly discovered cas genes with interesting properties could eventually circumvent the 
prominence of NHEJ in other organisms such as mammalian cells. For example, two 
independent labs recently reported a method for large DNA insertions using CRISPR-
associated transposases, which would ultimately eliminate the dependency on the 
endogenous repair machinery to perform genetic engineering (201, 202). This is relevant 
in the context of producing oleochemicals in oleaginous yeast as many engineering 
challenges come from their predominant NHEJ repair machinery.  
 
5.3 Mundus Novus 
One aspect that remains underexploited in the metabolic engineering field is the utilization 
of CRISPR gRNA libraries for genome-wide high-throughput screening (203). In 
comparison to rational approaches, which predominate the field, appropriate screening 
platforms could enable unbiased and high-level perturbations of gene networks (204). In 
Chapter III, after characterizing dCas9-VPR as a robust tool for graded gene regulation 
(Paper IV), we harnessed the versatility of gRNA libraries with an encoded biosensor to 
identify optimal gene expression of (non-obvious) genes contributing to 3-HP production 
(Paper V). As with our study, model-guided strategies can provide a promising platform 
for inferring novel biological phenotypes, ultimately reducing the number of targeted 
genes. However, while our FBA simulations predicted candidate genes for screening and 
subsequently reduced the number of genes to target, most of the predicted genes were not 
represented among the enriched gRNAs. Here, potential issues arising from incorrect in 
silico predictions could come from the biomass composition set to be invariant at different 
growth rates, for which slight changes in the coefficients can have major effects on the 
obtained flux distribution. Even though the yeast GEM used in this study is extensively 
curated, many gaps might remain, e.g. dead-end metabolites and unconnected reactions 
(39, 205). Altogether, this highlights the need for a better scoring associated to these genes, 
and more importantly the relevance of the suggested genes. 
 
Also, because of its unpredictable outcome, systematic screenings with combinatorial 
gRNA libraries remain challenging as gene interference is difficult to predict solely based 
on the gRNA position. In Paper V, to mitigate these disadvantages, we extensively covered 
each promoter targeted with up to 21 gRNAs. Notably, applying an extensive coverage 
could also help to elucidate functional regulatory sites in the promoter studied. Indeed, 
mapping the regulatory effect of each gRNA targeted to a transcription factor binding sites 
could eventually provide more insight into the importance of each transcription factors on 
the targeted promoter. Also, covering each promoter by up to 21 gRNAs allowed to, 
fortuitously, retrieve non-obvious transcriptional regulation that ultimately significantly 
increased 3-HP production, e.g. SPO23 and HTA1. Likewise, Joung and colleagues targeted 
 
  
51 
 
 
promoters of more than 10,000 long non-coding RNAs using a CRISPR activation 
screening approach and identified several loci that drive anticancer drug resistance in 
melanoma cells (206). It would be of great interest to apply a similar strategy in yeast to 
systematically discover the functions of non-obvious elements that influence specific 
cellular processes. Conversely to the numerous large-scale studies performed in 
mammalian cells, the “yeast field” lacks a proper CRISPR database with sufficient 
knowledge needed to perform high-fidelity genetic engineering experiments, e.g. a list of 
all experimentally validated gRNAs used for gene knockout or gene regulation in yeast 
(207–210). The advantages brought by having such database would invaluably contribute 
to more complex combinatorial screenings, which would allow further elucidation of new 
emergent synergies (206).  
 
Besides novel gene regulation, CRISPR tools can also be deployed for synthetic evolution 
of enzymes (211, 212). For example, combinatorial libraries generated by error-prone PCR 
can be efficiently integrated with CRISPR/Cas9, ultimately enabling the screening of 
hundreds of thousands of novel gene variants (213). By extension, base-editing systems 
such as those described in Chapter IV, would provide better control over which specific 
region to mutagenize compared to error-prone PCR (189, 214–216). 
  
5.4 Radical redesign of the yeast genome 
The Sc2.0 project, which ambitiously aim to synthesize and assemble the whole S. 
cerevisiae genome, has already been completed to more than one-third, with seven 
synthetic chromosomes completed (191). Sc2.0 chromosomes are designed to have all 
TAG stop codons replaced by TAA, as well as all repetitive elements removed with the 
exception of tRNAs, which are relocated to a new chromosome. Importantly, detailed 
physiologic assessments later revealed almost no phenotypic impact on the strains 
harboring these synthetic chromosomes, e.g. wild-type growth rates and same protein 
abundance (217). The complete synthesis has been estimated to be achieved before 2025 
and will cost approximately US$1.25 million (191, 218). On the other side, using 
CRISPR/Cas9 technology, top-down approaches for minimizing the yeast genome have 
started to emerge (219, 220). Promiscuous gRNAs, presented in Paper VII, could be 
theoretically be employed for a same type of applications. Here, our algorithm predicted a 
single promiscuous gRNAs capable to target 148 of these elements at once, and with proper 
setup could be utilized for minimizing of redundant genetic material, as with the Sc2.0 
project. Additionally, these promiscuous gRNAs could also enhance in vivo combinatorial 
chromosomal rearrangements to accelerate adaptive evolution of strains with improved 
genetic backgrounds (221).  
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5.5 Advancing CRISPR technologies through yeast engineering 
In the first reports of Cas9 application in human cell lines, the authors cautioned on the 
specificity of achieving significant cleavage, as well as cautioned on the unwanted off-
target effects often accompanied with genome engineering tool (47, 61). Scientists have 
since aspired to develop the next-generation of engineered Cas9 with higher fidelity, 
different PAM specificity, increased nuclease activity, as well as smaller protein length (57, 
63, 65, 75, 222, 223). In this context, several studies have exploited yeast as a workhorse 
organism for in vivo directed evolution of protein engineering for CRISPR applications 
(184, 222). Casini and colleagues screened a mutagenized library of Cas9 for both on- and 
off-target activity using a yeast-based assay established with a promiscuous gRNA 
targeting TRP1 to assess the on-target specificity, and ADE2 for off-targeting (222). The 
resulting screening yielded four beneficial mutations whose combination results in an 
engineered Cas9 with drastically less off-target than the wild-type version while retaining 
sufficient on-target efficiency. Also, Abuddayeh and colleagues recently developed a 
unique C to U RNA editor, where the adenine deaminase domain of ADAR2 was 
mutagenized into a cytidine deaminase via multiple rounds of library screening in yeast 
(184). Indeed, in order to select increased C to U activity, they aimed to reverse mutations 
in the yeast HIS3 marker. Deciphering genes and pathways impacting the specificity of the 
cleavage would also be of utmost interest. In this context, future strategies could employ 
yeast deletion or overexpression libraries as they provide a unique advantage compared to 
other tools.  
 
Additionally, the advent of machine-learning algorithms for protein engineering could also 
enable the discovery of nontrivial Cas functions (224, 225). Notably, machine learning 
algorithms have already been employed to reliably predict NHEJ patterns from the repair 
of double-strand breaks in mammalian cells (225, 226). Finally, besides directed evolution, 
several studies have employed yeast to shed light on idiosyncratic patterns of HR repair 
mechanisms in heterozygous diploid cells (227, 228). Gorter de Vries and colleagues 
recently reported loss of heterozygosity of entire chromosome arms from unexpected HR 
events in heterozygous diploid yeast cells (228). Since these events could have dramatic 
consequences in human gene therapy or gene drive setups, preliminary yeast-based studies 
could eventually elucidate key factors to optimize these experiments.  
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